Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 28	CA/CAplus patent coverage enhanced
NEWS 3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5	JUL 28	STN Viewer performance improved
NEWS 6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 9	AUG 15	CAplus currency for Korean patents enhanced
NEWS 10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 14	SEP 29	IFICLS enhanced with new super search field
NEWS 15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS 22	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:24:31 ON 25 NOV 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 19:24:41 ON 25 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 NOV 2008 HIGHEST RN 1075293-66-1
DICTIONARY FILE UPDATES: 24 NOV 2008 HIGHEST RN 1075293-66-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567269a.str



chain nodes :
10 11 12 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-10 10-11 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-10 3-4 4-5 4-7 5-6 5-9 8-9 10-11 11-12
exact bonds :
7-8
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 14:Atom
Generic attributes :
14:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l`
L1 HAS NO ANSWERS
'L` ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
ENTER STRUCTURE FORMAT (SIM), NOS:0
'0' IS NOT A VALID STRUCTURE FORMAT KEYWORD
ENTER STRUCTURE FORMAT (SIM), NOS:nos
L1 STR

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 19:25:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2239 TO ITERATE

100.0% PROCESSED     2239 ITERATIONS                                294 ANSWERS
SEARCH TIME: 00.00.01

L2          294 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.36     178.57

FILE 'CAPLUS' ENTERED AT 19:25:15 ON 25 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Nov 2008  VOL 149 ISS 22
FILE LAST UPDATED: 24 Nov 2008  (20081124/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html
```

```
=> s l2 full
L3          38 L2

=> d ibib abs hitstr tot
```

L3 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:1073428 CAPLUS
DOCUMENT NUMBER: 149:332335
TITLE: Imidazo[1,2-a]pyridines as endothelial NO synthase expression upregulators, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Zoller, Gerhard; Strobel, Hartmut; Will, David William; Wohlfart, Paulus
PATENT ASSIGNEE(S): Sanofi-Aventis, Germany
SOURCE: PCT Int. Appl., 114pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008104278	A1	20080904	WO 2008-EP1150	20080215
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1964840	A1	20080903	EP 2007-4120	20070228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: EP 2007-4120 A 20070228
OTHER SOURCE(S): MARPAT 149:332335
GI



I



II

AB The invention relates to imidazo[1,2-a]pyridines of formula I, which modulate the transcription of endothelial nitric oxide (NO) synthase. In compds. I, R1 is H or C1-6 alkyl; R2 is H, OH, or C1-6 alkyl; R3 is Br,

cyano, nitro, amino, carboxy, (un)substituted carbamoyl, (un)substituted acylamino, C1-6 alkoxycarbonyl, or (un)substituted carbimidamoyl; each R4 is independently H or C1-6 alkyl; n is 0-5; each R5 is independently halo, OH, optionally fluoro-substituted C1-6 alkyl, C1-3 alkoxy-C1-3 alkyl, optionally fluoro-substituted C1-6 alkoxy, C3-7 cycloalkyl, (un)substituted C6-14 aryl, etc., or R1 and R5 together form a C1-2 alkylene or C2 alkenylene bridge when R5 is attached in the ortho-position of the Ph ring; including physiol. acceptable salts thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising an ED of at least one compound of formula I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of cardiovascular diseases, such as atherosclerosis, thrombosis, coronary artery disease, hypertension, and cardiac insufficiency. Heterocyclization of 2-bromo-1-(4-fluorophenyl)ethanone with Me 6-aminonicotinate gave imidazopyridine II. Preferred compds. of the invention, e.g., II, expressed EC50 values below 500 nM for activation of eNOS transcription.

IT 900534-23-8P, N-[2-(4-Fluorophenyl)imidazo[1,2-a]pyridin-6-yl]acetamide 1051397-40-0P, N-[2-(4-Fluorophenyl)imidazo[1,2-a]pyridin-6-yl]formamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazo[1,2-a]pyridines as endothelial NO synthase expression upregulators)

RN 900534-23-8 CAPLUS
CN Acetamide, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 1051397-40-0 CAPLUS
CN Formamide, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:1058173 CAPLUS
DOCUMENT NUMBER: 149:332330
TITLE: Imidazo[1,2-a]pyridines as endothelial NO synthase expression upregulators, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Zoller, Gerhard; Strobel, Hartmut; Will, David William; Wohlfart, Paulus
PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.
SOURCE: Eur. Pat. Appl., 60pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1964840	A1	20080903	EP 2007-4120	20070228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2008104278	A1	20080904	WO 2008-EP1150	20080215
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2007-4120 A 20070228
GI



I



II

AB The invention relates to imidazo[1,2-a]pyridines of formula I, which modulate the transcription of endothelial nitric oxide (NO) synthase. In

compds. I, R1 is H or C1-6 alkyl; R2 is H, OH, or C1-6 alkyl; R3 is Br, cyano, nitro, amino, carboxy, (un)substituted carbamoyl, (un)substituted acylamino, C1-6 alkoxycarbonyl, or (un)substituted carbimidamoyl; each R4 is independently H or C1-6 alkyl; n is 0-5; each R5 is independently halo, OH, optionally fluoro-substituted C1-6 alkyl, C1-3 alkoxy-C1-3 alkyl, optionally fluoro-substituted C1-6 alkoxy, C3-7 cycloalkyl, (un)substituted C6-14 aryl, etc., or R1 and R5 together form a C1-2 alkylene or C2 alkenylene bridge when R5 is attached in the ortho-position of the Ph ring; including physiol. acceptable salts thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising an ED of at least one compound of formula I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of cardiovascular diseases, such as atherosclerosis, thrombosis, coronary artery disease, hypertension, and cardiac insufficiency. Heterocyclization of 2-bromo-1-(4-fluorophenyl)ethanone with Me 6-aminonicotinate gave imidazopyridine II. Preferred compds. of the invention, e.g., II, expressed EC50 values below 500 nM for activation of eNOS transcription.

IT 900534-23-8P, N-[2-(4-Fluorophenyl)imidazo[1,2-a]pyridin-6-yl]acetamide 1051397-40-0P, N-[2-(4-Fluorophenyl)imidazo[1,2-a]pyridin-6-yl]formamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazo[1,2-a]pyridines as endothelial NO synthase expression upregulators)

RN 900534-23-8 CAPLUS
CN Acetamide, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 1051397-40-0 CAPLUS
CN Formamide, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:1009981 CAPLUS
DOCUMENT NUMBER: 149:288937
TITLE: Preparation of amino acid derivatives as gut microsomal triglyceride transport protein inhibitors
INVENTOR(S): Vu, Chi B.
PATENT ASSIGNEE(S): Sirtris Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 198pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008100423	A1	20080821	WO 2008-US1681	20080208
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080249130	A1	20081009	US 2008-69429	20080208
PRIORITY APPLN. INFO.:			US 2007-900491P	P 20070209
			US 2007-958301P	P 20070702

OTHER SOURCE(S): MARPAT 149:288937
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to amino acid derivs. I [R1 is Ph, heterocyclyl, or heteroaryl; R2 is CONRa, CHRaNRa; R3 is -L1-R8-L2- (R8 is carbocyclyl or heterocyclyl, L1 is a direct bond or CH2 and L2 is a direct bond, CH2, S, or O, where at least one of L1 and L2 is a direct bond); R4 is H, alkyl, cycloalkyl, acyl, etc.; R5 is alkyl, cycloalkyl, acyl, etc.; or R4R5N is heterocyclyl; R6 is halo, alkyl, or alkoxy; R7 is a group given for R6 or -X-R9, where X is a bond, O, S, NRa, etc. and R9 is alkyl, carbamoylmethyl, cycloalkyl, etc.; Ra is H or alkyl; m is 0-5; n is 0-4] or their pharmaceutically-acceptable salts, which are inhibitors of gut microsomal triglyceride transfer protein (MTP) and are useful in treating diseases or conditions such as diabetes and obesity. Thus, compound II, prepared by amidation of 6-(4'-tert-butylbiphenyl-2-ylcarboxamido)benzo[d]thiazole-2-carboxylic acid (preparation given) with (S)-2-amino-N-(4-fluorobenzyl)-N-methyl-2-phenylacetamide hydrochloride salt, showed IC50 = 3.0 and 13.9/3.0 nM in ApoB secretion inhibition and in vitro inhibition of MTP assays, resp.

IT 1048366-41-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as gut microsomal triglyceride transport protein inhibitors)

RN 1048366-41-1 CAPLUS
CN Imidazo[1,2-a]pyridine-2-carboxamide, 6-[[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-N-[(1S)-2-[[(4-fluorophenyl)methyl]methylamino]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1048367-56-1P 1048367-57-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as gut microsomal triglyceride transport protein inhibitors)
RN 1048367-56-1 CAPLUS
CN Imidazo[1,2-a]pyridine-2-carboxylic acid, 6-[[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 1048367-57-2 CAPLUS
CN Imidazo[1,2-a]pyridine-2-carboxylic acid, 6-[[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:318977 CAPLUS
DOCUMENT NUMBER: 148:355787
TITLE: Preparation of imidazopyridines and related compounds for the treatment of Duchenne muscular dystrophy
INVENTOR(S): Wynne, Graham Michaell; Wren, Stephen Paul; Lecci, Cristina
PATENT ASSIGNEE(S): Summit Corporation PLC, UK
SOURCE: PCT Int. Appl., 59pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008029152	A2	20080313	WO 2007-GB3377	20070907
WO 2008029152	A3	20080508		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:		
GB 2006-17739	A	20060908
GB 2006-19282	A	20060929
GB 2006-23985	A	20061130

OTHER SOURCE(S): MARPAT 148:355787
GI



I



II

AB Title compds. I [A1-A5 = N or CR1; Y, Z = O, S(O)n, NR4, etc.; R4 = H or substituent; further detail on R4 is given; n = 0-2; Y and Z cannot both represent O, or S, or together represent O-S; when an adjacent pair of

A1-A4 each represents CR1, then the adjacent carbon atoms, together with their substituents may form a ring] or pharmaceutically acceptable salts were prepared For example, reaction of 2,5-diaminopyridine·2HCl with 2-bromo-1-(4-chlorophenyl)ethanone afforded compound II in 21% yield. Biol. activity for treating Duchenne muscular dystrophy was assesed using the luciferase reporter assay in murine H2K cells, e.g., compound II showed above 401% activity relative to control. Compds. I are also claimed useful for the therapeutic and/or prophylactic treatment of Becker muscular dystrophy or cachexia.

IT 1011709-39-9P 1011709-42-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazopyridines and related compds. for treatment of Duchenne muscular dystrophy)

RN 1011709-39-9 CAPLUS
CN Carbamic acid, N-[2-(3,4-dichlorophenyl)imidazo[1,2-a]pyridin-6-yl]-, ethyl ester (CA INDEX NAME)



RN 1011709-42-4 CAPLUS
CN Carbamic acid, N-[2-(3,4-dichlorophenyl)imidazo[1,2-a]pyridin-6-yl]-N-methyl-, ethyl ester (CA INDEX NAME)



IT 900534-23-8P 1011709-34-4P 1011709-35-5P
1011709-37-7P 1011709-38-8P 1011709-40-2P
1011709-49-1P 1011709-51-5P 1011709-52-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridines and related compds. for treatment of Duchenne muscular dystrophy)

RN 900534-23-8 CAPLUS
CN Acetamide, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 1011709-34-4 CAPLUS
CN Propanamide, N-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]-2-methyl- (CA INDEX NAME)



RN 1011709-35-5 CAPLUS
CN Propanamide, N-[2-(3,4-dichlorophenyl)imidazo[1,2-a]pyridin-6-yl]-2-methyl- (CA INDEX NAME)



RN 1011709-37-7 CAPLUS
CN Acetamide, N-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 1011709-38-8 CAPLUS
CN Acetamide, N-[2-(3,4-dichlorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 1011709-40-2 CAPLUS
CN Cyclopropanecarboxamide, N-[2-(3,4-dichlorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 1011709-49-1 CAPLUS
CN Acetamide, N-[2-(2-naphthalenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 1011709-51-5 CAPLUS
CN Butanamide, N-[2-(3,4-dichlorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 1011709-52-6 CAPLUS
CN Butanamide, N-[2-(3,4-dichlorophenyl)imidazo[1,2-a]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



L3 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:156992 CAPLUS
DOCUMENT NUMBER: 148:215052
TITLE: Preparation of imidazo[1,2-a]pyridine derivatives as skeletal muscle myosin modulators
INVENTOR(S): Muci, Alex; Finer, Jeffrey T.; Morgan, Bradley P.; Russell, Alan James; Morgans, David J., Jr.
PATENT ASSIGNEE(S): Cytokinetics, Incorporated, USA
SOURCE: PCT Int. Appl., 75pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008016648	A2	20080207	WO 2007-US17191	20070731
WO 2008016648	A3	20081030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

US 2006-834906P	P	20060801
US 2006-836747P	P	20060809
US 2007-920921P	P	20070330

OTHER SOURCE(S): MARPAT 148:215052
GI



I



II

AB Title compds. represented by the formula I [wherein R1 = H, alkyl, acyl, etc.; R2 = H, (un)substituted (cyclo)alkyl or alkoxycarbonyl; R3 = (un)substituted (cyclo)alkyl or (hetero)aryl; R4-R7 = independently H, halo, (un)substituted alkyl, etc.; and pharmaceutically acceptable salts thereof] were prepared and tested as skeletal muscle myosin modulators. For example, reaction of 2-amino-5-picoline with 4-hydroxybenzaldehyde and cyclopentyl isocyanide gave II in 66% yield, which had 13.5754 for SKM Myofibril AC1.4 (median). I are useful for modulating di-skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, neuromuscular disease, and other indications.

IT 1005410-97-8P, N-[3-[(3-Chlorobenzyl)amino]-2-(2-hydroxyphenyl)imidazo[1,2-a]pyridin-6-yl]-3-hydroxypropanamide
1005410-98-9P, N-[3-[(3-Chlorobenzyl)amino]-2-(2-hydroxyphenyl)imidazo[1,2-a]pyridin-6-yl]-3-methoxypropanamide
1005410-99-0P, N-[3-[(4-Fluorobenzyl)amino]-2-(2-hydroxyphenyl)imidazo[1,2-a]pyridin-6-yl]-3-hydroxypropanamide
1005411-00-6P, N-[3-[(4-Fluorobenzyl)amino]-2-(2-hydroxyphenyl)imidazo[1,2-a]pyridin-6-yl]-3-methoxypropanamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-a]pyridine derivs. as skeletal muscle myosin modulators)

RN 1005410-97-8 CAPLUS
CN Propanamide, N-[3-[[(3-chlorophenyl)methyl]amino]-2-(2-hydroxyphenyl)imidazo[1,2-a]pyridin-6-yl]-3-hydroxy- (CA INDEX NAME)





RN 1005410-98-9 CAPLUS
CN Propanamide, N-[3-[[(3-chlorophenyl)methyl]amino]-2-(2-hydroxyphenyl)imidazo[1,2-a]pyridin-6-yl]-3-methoxy- (CA INDEX NAME)





RN 1005410-99-0 CAPLUS
CN Propanamide, N-[3-[[(4-fluorophenyl)methyl]amino]-2-(2-hydroxyphenyl)imidazo[1,2-a]pyridin-6-yl]-3-hydroxy- (CA INDEX NAME)



RN 1005411-00-6 CAPLUS
CN Propanamide, N-[3-[[(4-fluorophenyl)methyl]amino]-2-(2-hydroxyphenyl)imidazo[1,2-a]pyridin-6-yl]-3-methoxy- (CA INDEX NAME)



L3 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:12488 CAPLUS
DOCUMENT NUMBER: 148:121708
TITLE: 2-Benzoylimidazo[1,2-a]pyridine derivatives, their preparation and their therapeutic use for NOT receptor-associated disease treatment
INVENTOR(S): El, Ahmad Youssef; Peyronel, Jean Francois
PATENT ASSIGNEE(S): Sanofi Aventis, Fr.
SOURCE: Fr. Demande, 32pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2903105	A1	20080104	FR 2006-6010	20060703
WO 2008003854	A2	20080110	WO 2007-FR1123	20070703
WO 2008003854	A3	20080306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: FR 2006-6010 A 20060703
OTHER SOURCE(S): MARPAT 148:121708
GI



I



II

AB The invention is related to the preparation of title compds. I [X = (un)substituted phenyl; R1 = H, halo, alkoxy, NH2, etc.; R2 = H, alk(en/yn)yl, CN, alkoxycarbonyl, CHO, etc.; R3 = H, alkyl, halo, OH; R4 = H, halo ; at least one of R1-R4 is not H; with the exclusion of specified compds.] and their acid addition salts for the preparation of a medicament for the treatment and the prevention of the diseases in which the NOT receptor is implicated. Thus, cyclization of with 2-amino-5-methylpyridine with 3-bromo-1-phenylpropane-1,2-dione and acidulation with HCl in dioxane/diethyl ether gave imidazopyridine salt II•HCl. I were modulators of NOT; selected I displayed an average binding affinity towards human NOT receptor.
IT 1000845-22-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzoylimidazopyridines for NOT receptor-associated disease treatment)

RN 1000845-22-6 CAPLUS

CN Acetamide, N-(2-benzoylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



IT 1009095-25-3P

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prophetic intermediate; preparation of benzoylimidazopyridines for NOT receptor-associated disease treatment)

RN 1009095-25-3 CAPLUS

CN Acetamide, N-(3-benzoylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:814035 CAPLUS
DOCUMENT NUMBER: 147:211857
TITLE: Preparation of aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors
INVENTOR(S): Buettelmann, Bernd; Han, Bo; Knust, Henner; Thomas, Andrew
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007082806	A1	20070726	WO 2007-EP50137	20070108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007207053	A1	20070726	AU 2007-207053	20070108
CA 2636112	A1	20070726	CA 2007-2636112	20070108
EP 1979350	A1	20081015	EP 2007-703688	20070108
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20070179178	A1	20070802	US 2007-654183	20070116
MX 200808834	A	20080716	MX 2008-8834	20080708
KR 2008075924	A	20080819	KR 2008-717297	20080716

PRIORITY APPLN. INFO.: EP 2006-100426 A 20060117
WO 2007-EP50137 W 20070108

OTHER SOURCE(S): MARPAT 147:211857

GI



I



II

AB Title compds. I [R1 = H, halo, OH, alkyl, OCH2Ph or OCH2COR; R2 = H, halo, alkyl, alkynyl, NH2, etc.; R3 = H, halo, CN, alkyl, alkynyl, etc.; R4 = H or 5- to 6-membered heteroaryl; R5 = alkyl or cycloalkyl], and their pharmaceutically acceptable acid addition salts, are prepared and disclosed for the treatment of Alzheimer's disease via GABA receptors.(no data). Thus, e.g., II was prepared by cyclocondensation of 4-(bromoacetyl)-5-methyl-3-phenylisoxazole with 2-aminopyridine. The affinity of I at GABA A receptor subtypes was measured in radioligand binding assays with Ki value typically ≤ 300 nM. I showed high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.

IT 945103-50-4P, 2-Cyclopropyl-N-[2-(5-methyl-3-phenylisoxazol-4-yl)imidazo[1,2-a]pyridin-6-yl]acetamide 945103-51-5P, N-[2-(5-Methyl-3-phenylisoxazol-4-yl)imidazo[1,2-a]pyridin-6-yl]-2-(pyridin-3-yl)acetamide 945103-52-6P, Cyclopropanecarboxylic acid N-[2-(5-methyl-3-phenylisoxazol-4-yl)imidazo[1,2-a]pyridin-6-yl]amide 945103-53-7P, Cyclobutanecarboxylic acid N-[2-(5-methyl-3-phenylisoxazol-4-yl)imidazo[1,2-a]pyridin-6-yl]amide 945103-54-8P, Cyclopentanecarboxylic acid N-[2-(5-methyl-3-phenylisoxazol-4-yl)imidazo[1,2-a]pyridin-6-yl]amide 945103-55-9P, N-[2-(5-Methyl-3-phenylisoxazol-4-yl)imidazo[1,2-a]pyridin-6-yl]benzamide 945103-56-0P, N-[2-(5-Methyl-3-phenylisoxazol-4-yl)imidazo[1,2-a]pyridin-6-yl]nicotinamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of arylisoxazolylimidazo[1,2-a]pyridine useful for treatment of Alzheimer's disease via GABA receptors)

RN 945103-50-4 CAPLUS
CN Cyclopropaneacetamide, N-[2-(5-methyl-3-phenyl-4-isoxazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 945103-51-5 CAPLUS
CN 3-Pyridineacetamide, N-[2-(5-methyl-3-phenyl-4-isoxazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 945103-52-6 CAPLUS
CN Cyclopropanecarboxamide, N-[2-(5-methyl-3-phenyl-4-isoxazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 945103-53-7 CAPLUS
CN Cyclobutanecarboxamide, N-[2-(5-methyl-3-phenyl-4-isoxazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 945103-54-8 CAPLUS
CN Cyclopentanecarboxamide, N-[2-(5-methyl-3-phenyl-4-isoxazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 945103-55-9 CAPLUS
CN Benzamide, N-[2-(5-methyl-3-phenyl-4-isoxazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 945103-56-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(5-methyl-3-phenyl-4-isoxazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



IT 945103-70-8P, [2-(5-Methyl-3-phenylisoxazol-4-yl)imidazo[1,2-a]pyridin-6-yl]carbamic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of arylisoxazolylimidazo[1,2-a]pyridine useful for treatment of Alzheimer's disease via GABA receptors)

RN 945103-70-8 CAPLUS

CN Carbamic acid, N-[2-(5-methyl-3-phenyl-4-isoxazolyl)imidazo[1,2-a]pyridin-6-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:619446 CAPLUS
DOCUMENT NUMBER: 147:31100
TITLE: Preparation of 6-iodoimidazo[1,2-a]pyridine, 6-iodobenzothiazole, 6-(fluoromethyl)- or 6-fluoroimidazo[1,2-a]pyridine, and N-(imidazo[1,2-a]pyridin-6-yl)-2-fluoroacetamide derivatives as diagnostic agents and remedies for disease caused by amyloid aggregation and/or deposition
INVENTOR(S): Bando, Kazunori; Taguchi, Kazumi
PATENT ASSIGNEE(S): Daiichi Radioisotope Labs., Ltd., Japan
SOURCE: PCT Int. Appl., 116pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063946	A1	20070607	WO 2006-JP323955	20061130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1956013	A1	20080813	EP 2006-833758	20061130
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: JP 2005-346676 A 20051130
WO 2006-JP323955 W 20061130

OTHER SOURCE(S): MARPAT 147:31100
GI



I



II

AB It is intended to provide diagnostic agents which specifically bind to an amyloid aggregate or deposit, readily pass through blood brain barrier, and are not metabolized in brain and thus enable the visualization or quantification of a disease caused by the amyloid aggregation and/or deposition. Namely, compds. represented by the following general formula

(I) (X1 = optionally substituted bicyclic heterocycle group; X2 = H, halogen atom, a chelate-forming group; the ring A = benzene or pyridine ring; the ring B = optionally substituted 5-membered aromatic heterocycle group which is bonded to the benzene ring or the pyridine ring in the formula at the carbon atom), salts thereof, solvates of the same, or transition metal complexes of the same are prepared These compds. are useful as diagnostic agents (imaging agents) or preventive or therapeutic agents for diseases caused by amyloid aggregation and/or deposition, e.g. amyloidosis, Alzheimer's disease, Down's syndrome, Creutzfeldt-Jakob disease, type II diabetes, dialysis amyloidosis, AA amyloidosis, and Parkinson's disease. They are also useful for screening drugs for the prevention and/or treatment of diseases caused by amyloid aggregation and/or deposition. Thus, a solution of 5-(4-[6-(tributylstannyl)imidazo[1,2-a]pyridin-2-yl]phenyl)-1,3-oxazole and [125I]NaI in 0.3 M sodium phosphate buffer was treated with an aqueous solution of sodium p-toluenesulfonchloramide and the resulting mixture was allowed to react at room temperature for 2 min and quenched by adding an aqueous solution of sodium pyrosulfite to give [125I]5-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenyl]-1,3-oxazole (II). II inhibited the binding of amyloid β (1-40) peptide hydrochloride to IMPY, PIB, FDDNP, thioflavin T, Congo Red, 5-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenyl]-1,3-oxazole (compound prepared), and 6-iodo-2-[4-(1H-3-pyrazolyl)phenyl]imidazo[1,2-a]pyridine (compound prepared) with IC50 of 29.3, 42.9, 1,050, 895, >5,000, 1.23, and 9.72 μM, resp. Number Abc.

IT 938461-32-6P, N-[2-[4-(1,3-Oxazol-5-yl)phenyl]imidazo[1,2-a]pyridin-6-yl]-2-chloroacetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of iodoimidazo[1,2-a]pyridine, iodobenzothiazole, and fluorinatediodoimidazo[1,2-a]pyridine derivs. as diagnostics or drugs for diseases caused by amyloid aggregation and/or deposition)

RN 938461-32-6 CAPLUS

CN Acetamide, 2-chloro-N-[2-[4-(5-oxazolyl)phenyl]imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



IT 938461-29-1P, N-[2-[4-(1,3-Oxazol-5-yl)phenyl]imidazo[1,2-a]pyridin-6-yl]-2-fluoroacetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of iodoimidazo[1,2-a]pyridine, iodobenzothiazole, and fluorinatediodoimidazo[1,2-a]pyridine derivs. as diagnostics or drugs for diseases caused by amyloid aggregation and/or deposition)

RN 938461-29-1 CAPLUS

CN Acetamide, 2-fluoro-N-[2-[4-(5-oxazolyl)phenyl]imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:350120 CAPLUS
DOCUMENT NUMBER: 146:358851
TITLE: Aryl-substituted imidazo[1,2-a]pyridine derivatives as C3a receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Claffey, Michelle Marie; Goldstein, Steven Wayne
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 69pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007034278	A2	20070329	WO 2006-IB2561	20060918
WO 2007034278	A3	20070518		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-718451P P 20050919
OTHER SOURCE(S): MARPAT 146:358851
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to aryl-substituted imidazo[1,2-a]pyridines and related compds. of general formula I, which are antagonists of the mammalian C3a receptor. In compds. I, W is (un)substituted pyrazolyl, (un)substituted oxazolyl, (un)substituted thiazolyl, or (un)substituted thienyl; n is 3, 4, or 5; each Z is independently selected from CR1, CHR1, C(=O), N, NR1, N(=O), S, and O, where the ring containing Z is a heterocyclyl or heteroaryl ring containing 1-3 heteroatoms independently selected from N, O, and S, and each R1 is independently H, halo, (un)substituted C1-8 alkyl, (un)substituted C1-6 alkoxy, (un)substituted sulfamoyl, (un)substituted C3-10 cycloalkyl, etc., and a bond between two groups Z may be a single bond or a double bond; and U, V, X, and Y are independently selected from CH, CF, and N, where the ring contains no more than two nitrogen atoms. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and optionally a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of chronic inflammatory diseases including inflammations in the central nervous system, peripheral nervous system, lungs, and bone joints. Deprotonation of 4-bromoacetophenone followed by condensation with Et trifluoroacetate and heterocyclocondensation with hydrazine gave pyrazole II, which was N-methylated, lithiated and condensed with N-methoxy-N-methyl-2-chloroacetamide resulting in the formation of chloroacetophenone III. Condensation of III with

6-chloropyridazin-3-ylamine and heterocyclization gave imidazopyridazine IV, which underwent coupling with 2,4-dimethoxybenzylamine and acidic cleavage to give amine V. The compds. of the invention are antagonists of C3a receptors, e.g., compound V expressed IC50 value of 18 nM.

IT 929898-83-9P, N-[2-[4-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)phenyl]imidazo[1,2-a]pyridin-6-yl]acetamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aryl-substituted imidazopyridine derivs. as C3a receptor antagonists)

RN 929898-83-9 CAPLUS

CN Acetamide, N-[2-[4-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



IT 929898-84-0P, N-[2-[4-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)phenyl]imidazo[1,2-a]pyridin-6-yl]acetamide p-toluenesulfonic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl-substituted imidazopyridine derivs. as C3a receptor antagonists)

RN 929898-84-0 CAPLUS

CN Acetamide, N-[2-[4-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]imidazo[1,2-a]pyridin-6-yl]-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 929898-83-9
CMF C20 H16 F3 N5 O



CM 2

CRN 104-15-4
CMF C7 H8 O3 S


Me
HO3S

L3 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1001132 CAPLUS
DOCUMENT NUMBER: 146:27744
TITLE: A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors
AUTHOR(S): Warshakoon, Namal C.; Wu, Shengde; Boyer, Angelique; Kawamoto, Richard; Sheville, Justin; Renock, Sean; Xu, Kevin; Pokross, Matthew; Evdokimov, Artem G.; Walter, Richard; Mekel, Marlene
CORPORATE SOURCE: Procter & Gamble Pharmaceuticals, Inc., Mason, OH, 45040, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(21), 5598-5601
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:27744
AB Utilizing modeling information from a recently resolved structure of human HIF-1α prolyl hydroxylase (EGLN1) and structure-based design, a novel series of imidazo[1,2-a]pyridine derivs. was prepared The activity of these compds. was determined in a human EGLN1 assay and a limited SAR was developed.
IT 915788-42-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(A novel series of imidazo[1,2-a]pyridine derivs. as HIF-1α prolyl hydroxylase inhibitors)
RN 915788-42-0 CAPLUS
CN Glycine, N-[[6-[(3-chlorobenzoyl)amino]imidazo[1,2-a]pyridin-2-yl]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:969755 CAPLUS
DOCUMENT NUMBER: 145:356641
TITLE: Preparation of fused pyrrolecarboxamides as a new class of GABA brain receptor ligands
INVENTOR(S): Albaugh, Pamela; Shaw, Kenneth; Hutchison, Alan
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: U.S., 49pp., Cont.-in-part of U.S. Ser. No. 387,311.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7109351	B1	20060919	US 2000-651207	20000830
ZA 2002001649	A	20030314	ZA 2002-1649	20020227
US 20050014939	A1	20050120	US 2004-909022	20040730

PRIORITY APPLN. INFO.: US 1999-387311 B2 19990831
US 1999-151789P P 19990831
US 2000-651207 A3 20000830

OTHER SOURCE(S): MARPAT 145:356641
GI



I



II

AB The title compds. [I; Y = H, OH, halo, etc.; T = halo, H, OH, etc.; W = O, NH, C(O), etc.; Z = OH, NH2, alkoxy, etc.; k, m = 0-3; R3-R6 = H, alkyl, CO2R11, etc. (wherein R11 = alkyl, cycloalkyl, etc.); or R3-R4 are taken together to form a cyclic moiety having 3-7 carbon atoms; or R5-R6 are taken together to form a cyclic moiety having 3-7 carbon atoms] which are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors, and therefore are useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure

disorders, overdose with benzodiazepine drugs and for enhancement of memory, were prepared E.g., a multi-step synthesis of II which showed Ki of 90 nM against GABAA receptor binding, was given. Pharmaceutical compns., including packaged pharmaceutical compns., comprising the compds. I are further provided. Compds. I are also useful as probes for the localization of GABAA receptors in tissue samples.

IT 329018-52-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused pyrrolecarboxamides as a new class of GABA brain receptor ligands)

RN 329018-52-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-imidazo[1,2-a]pyridin-6-yl-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:498785 CAPLUS
DOCUMENT NUMBER: 145:167153
TITLE: A general and efficient method for the copper-catalyzed cross-coupling of amides and thiophenols with 6-halo-imidazo[1,2-a]pyridines
AUTHOR(S): Enguehard-Gueiffier, Cecile; Thery, Isabelle; Gueiffier, Alain; Buchwald, Stephen L.
CORPORATE SOURCE: UFR des Sciences Pharmaceutiques, Laboratoire de Chimie Therapeutique EA 3857, Tours, 37200, Fr.
SOURCE: Tetrahedron (2006), 62(25), 6042-6049
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:167153
AB Convenient and efficient methods for the preparation of novel amide and 6-(phenylthio)imidazo[1,2-a]pyridine derivs. that utilize copper-catalyzed methodologies are reported. These methods are particularly noteworthy because of their exptl. simplicity and the low cost of the catalyst system.
IT 900534-23-8P 900534-24-9P 900534-25-0P
900534-26-1P 900534-27-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of imidazo[1,2-a]pyridine derivs. via copper-catalyzed cross-coupling of amide, formamide or urea with (halo)imidazo[1,2-a]pyridine)
RN 900534-23-8 CAPLUS
CN Acetamide, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 900534-24-9 CAPLUS
CN Formamide, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 900534-25-0 CAPLUS
CN Benzamide, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 900534-26-1 CAPLUS
CN Urea, N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]-N'-phenyl- (CA INDEX NAME)



RN 900534-27-2 CAPLUS
CN Carbamic acid, [2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:436738 CAPLUS
DOCUMENT NUMBER: 144:468203
TITLE: Preparation of novel fused imidazole derivatives as polo like kinase 1 (PLK1) inhibitors and anticancer agents
INVENTOR(S): Sato, Yoshiyuki; Kurihara, Hideki; Kamijo, Kaori; Onozaki, Yu; Tsujino, Toshiaki; Sugimoto, Tetsuya; Watanabe, Akiko; Mitsuya, Morihiro; Komatani, Hideya
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 216 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006049339	A1	20060511	WO 2005-JP20763	20051107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005301568	A1	20060511	AU 2005-301568	20051107
CA 2586259	A1	20060511	CA 2005-2586259	20051107
EP 1813613	A1	20070801	EP 2005-803283	20051107
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101098870	A	20080102	CN 2005-80046274	20051107
US 20080103136	A1	20080501	US 2007-667282	20070507
IN 2007DN04027	A	20070831	IN 2007-DN4027	20070529

PRIORITY APPLN. INFO.: JP 2004-323438 A 20041108
WO 2005-JP20763 W 20051107

OTHER SOURCE(S): MARPAT 144:468203

GI



I

AB Fused imidazole compds. such as imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrazine, and imidazo[1,2-b]pyridazine derivs. represented by the general formula (I) pharmaceutically acceptable salts or esters thereof [the ring A = five-membered aromatic heterocyclic group containing at least one heteroatom selected from N, S, and O atoms; A1, A2 = CH, N, NH, S, O; all of X2-X5 = C atoms, or one of X2-X5 = N atoms and the rest = carbon atoms wherein R2-R5 is attached to the N atom; R1 = H, 1 or 2 halo-substituted Me, halo, OH, NH2; R1-R5 = H, -Y1-Y2-Y3-Y4; wherein Y1 = a single bond, CH2 CHMe, O, S, SO, SO2, CO, CONH, NHCO; Y2 = a single bond, (un)substituted (CH2)4; Y3 = a single bond, (un)substituted NH, S, O, SO2; Y4 = H, each (un)substituted lower alkyl, etc.; R6, R6' = H,(un)substituted lower alkyl, cycloalkyl; or R6 and R6' together form oxo; R7 = aryl, heteroaryl; R8 = NH2, HO] are prepared These compds. are first known fused imidazole compds. with potent inhibitory activity against polo like kinase 1 (PLK1) and induce M phase arrest of cell cycle. Thus, Mitsunobu reaction of 3-hydroxy-5-imidazo[1,2-a]pyridin-2-yl-2-thiophenecarboxylic acid Me ester with 1-(2-nitrophenyl)ethanol using tributylphosphine and diisopropyl azodicarboxylate followed by saponification, acidification, and amidation gave 5-imidazo[1,2-a]pyridin-3-yl-3-[1-(2-nitrophenyl)ethoxy]-2-thiophenecarboxamide (II) which were separated by a Chiralcel OD column to give (R)- and (S)-II. One of (R)- and (S)-II showed IC50 of 12 nM μg/mL against both PLK1 and PLK1-T210D and induced M phase arrest of cell cycle in HeLaS3 cells with EC50 of 0.07 μM.

IT 886857-58-5P 886859-30-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of novel fused imidazole derivs. as polo like kinase 1 (PLK1) inhibitors and anticancer agents)

RN 886857-58-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-[acetyl[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]imidazo[1,2-a]pyridin-3-yl]-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 886859-30-9 CAPLUS
CN Carbamic acid, [2-[[3-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]imidazo[1,2-a]pyridin-6-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 886859-29-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel fused imidazole derivs. as polo like kinase 1 (PLK1) inhibitors and anticancer agents)
RN 886859-29-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[2-(dimethylamino)acetyl]amino]imidazo[1,2-a]pyridin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:343955 CAPLUS
DOCUMENT NUMBER: 144:390936
TITLE: Aryl nitrogen-containing bicyclic compounds and their preparation, pharmaceutical compositions, and protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases
INVENTOR(S): Patel, Vinod F.; Kim, Joseph L.; Geuns-Meyer, Stephanie D.; Chaffee, Stuart C.; Cee, Victor J.; Hodous, Brian L.; Bellon, Steven; Harmange, Jean-Christophe; Olivieri, Philip R.; Thaman, Maya C.; Dimauro, Erin F.; Buchanan, John L.; Mcgowan, David C.; Albrecht, Brian K.; Deak, Holly L.; Bemis, Jean E.; White, Ryan; Martin, Matthew W.; Habgood, Gregory J.; Tempest, Paul A.; Masse, Craig E.; Buckner, William H.; Herberich, Bradley J.; Graceffa, Russell; Zhang, Dawei; Xu, Shimin; Sham, Kelvin; Rzasa, Robert M.; Falsey, James Richard; Chakrabarti, Partha P.; Cao, Guo-Qiang; Tomlinson, Susan Ann; Pettus, Liping H.; Smith, Adrian Leonard; Paras, Nick A.; Liu, Gang; Demorin, Frenel F.; Tasker, Andrew; Reed, Anthony
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 876 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006039718	A2	20060413	WO 2005-US35873	20051003
WO 2006039718	A3	20060713		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070054916	A1	20070308	US 2005-240590	20050930
AU 2005292152	A1	20060413	AU 2005-292152	20051003
CA 2582029	A1	20060413	CA 2005-2582029	20051003
EP 1836174	A2	20070926	EP 2005-818381	20051003
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008515812	T	20080515	JP 2007-534914	20051003
MX 200703784	A	20070424	MX 2007-3784	20070329

PRIORITY APPLN. INFO.:

US 2004-615535P	P	20041001
US 2005-240590	A	20050930
WO 2005-US35873	W	20051003

OTHER SOURCE(S): CASREACT 144:390936; MARPAT 144:390936
GI



I



II

AB The invention comprises a class of compds. of formula I useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. Compds. of formula I wherein A1 and one of A2 and A3 are independently CR5 or N; B is a bond, CR5R6, CO, NR6, O, S, SO, or SO2; R1 is halo, haloalkyl, NO2, CN, H, NH2 and derivs., OH and derivs., SH and derivs., CHO and derivs., OC(O)R and derivs., CO2H and derivs., CONH2 and derivs., CSNH2 and derivs., NHCHO and derivs., NHC(S)H and derivs., NHCONH2 and derivs., NHCSNH2 and derivs., SO2H and derivs., SO2NH2 and derivs., etc.; R2, R4, and R5 are independently H, halo, haloalkyl, NO2, CN, OH and derivs., SH and derivs., NH2 and derivs., CHO and derivs., CO2H and derivs., CONH2 and derivs., NHCONH2 and derivs., SO2H and derivs., SO2NH2 and derivs., NHSO2H and derivs., (un)substituted C1-10 (hetero)alkyl, (un)substituted C2-10 alkenyl, (un)substituted C2-10 (hetero)alkynyl, (un)substituted 3- to 10-membered (hetero)cycloalkyl, (un)substituted 4- to 10-membered (hetero)cycloalkenyl, etc.; R3 is (un)substituted (un)saturated 5- to 8-membered (hetero)monocyclic, (un)substituted (un)saturated 6- to 12-membered (hetero)bicyclic, or (un)substituted (un)saturated 7- to 14-membered (hetero)tricyclic rings; R6 is H, (un)substituted C1-10 (hetero)alkyl, (un)substituted C2-10 (hetero)alkenyl, (un)substituted C2-10 (hetero)alkynyl, (un)substituted 3- to 10-membered (hetero)cycloalkyl, (un)substituted 4- to 10-membered (hetero)cycloalkenyl; and their stereoisomers, tautomers, solvates, pharmaceutically acceptable salts, derivs., and prodrugs thereof are claimed. Accordingly, the invention also comprises pharmaceutical compns. comprising the compds. of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compds. and compns. of the invention, and intermediates and processes useful for the preparation of compds. of the invention. Example compound II was prepared by boration of 3-iodo-4-methylbenzoic acid with bis(pinacolato)diboron; the resulting 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid was converted to the corresponding acid chloride, in situ, and reacted with 2-fluoro-5-trifluoromethylbenzeneamine to give N-(2-fluoro-5-fluoromethylphenyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, which underwent cross-coupling with 6-bromo-N-methylquinazolin-2-amine to give compound II. About 2000 invention compds. of formula I were prepared by similar procedures. All the invention compds. were tested for their protein kinase inhibitory activity. Example compound I along with many other invention compound showed good inhibitory activity. From the HTRF assay, the IC50 values for inhibition of Tie-2 was determined to be less than or equal to 1 μM for some

of the invention compds. For the inhibition of Lck kinase enzyme, the some of the exemplary compds. exhibited an average IC50 value of 25 μM or less and some invention compound exhibited an IC50 value of 1 μM or less, in the human HTRF assay. The invention compds. were also found to be active inhibitors or the VEGF kinase receptor. Furthermore, some of the invention compds. exhibited activities in the monocyte assay with IC50 values of 25 μM or less. Various compds. of the invention have selective inhibitory activity for specific kinase receptor enzymes, including Tie-2, Lck, p38 and VEGFR/KDR. Accordingly, the compds. of the invention would be useful in therapy as antineoplasia agents, antiinflammatory agents, or to minimize deleterious effects of Tie-2, Lck, VEGF and/or p38.

IT 882674-65-9P 882674-95-5P 882674-96-6P
882674-97-7P 882674-98-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl nitrogen-containing bicyclic compds. and their protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases)

RN 882674-65-9 CAPLUS
CN Benzamide, 3-(2-amino-6-quinazolinyl)-N-[2-(1,1-dimethylethyl)imidazo[1,2-a]pyridin-6-yl]-4-methyl- (CA INDEX NAME)



RN 882674-95-5 CAPLUS
CN Benzamide, N-[2-(1,1-dimethylethyl)imidazo[1,2-a]pyridin-6-yl]-4-methyl-3-[2-[[3-(4-morpholinyl)propyl]amino]-6-quinazolinyl]- (CA INDEX NAME)



RN 882674-96-6 CAPLUS
CN Benzamide, N-[2-(1,1-dimethylethyl)imidazo[1,2-a]pyridin-6-yl]-4-methyl-3-[2-[(1-methyl-4-piperidinyl)amino]-6-quinazolinyl]- (CA INDEX NAME)



RN 882674-97-7 CAPLUS

CN Benzamide, 3-[2-[[3-(diethylamino)propyl]amino]-6-quinazolinyl]-N-[2-(1,1-dimethylethyl)imidazo[1,2-a]pyridin-6-yl]-4-methyl- (CA INDEX NAME)



RN 882674-98-8 CAPLUS
CN Benzamide, N-[2-(1,1-dimethylethyl)imidazo[1,2-a]pyridin-6-yl]-4-methyl-3-[2-(methylamino)-6-quinazolinyl]- (CA INDEX NAME)



L3 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1310699 CAPLUS
DOCUMENT NUMBER: 144:36343
TITLE: Preparation of imidazopyridines and their use as activin receptor-like kinase 5 (ALK5) inhibitors for treatment of TGF β-related diseases
INVENTOR(S): Sato, Masakazu; Matsunaga, Yuiko; Asanuma, Hajime
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005343889	A	20051215	JP 2005-128778	20050427
PRIORITY APPLN. INFO.:			JP 2004-137544 A	20040506

OTHER SOURCE(S): MARPAT 144:36343
GI



I

AB Title compds. I [R1 = Ph substituted with halo, C1-6 alkyl(oxy), arylalkoxy, OH; (hetero)cyclyl-condensed benzene ring; R2 = (un)substituted 2-pyridyl, (un)substituted 2- or 4-thiazolyl] or their medically acceptable salts are prepared They are useful for treatment of alopecia, diabetic renal disease, cirrhosis, etc. Thus, cyclocondensation of 2-bromo-2-(4-methoxyphenyl)-1-pyridin-2-ylethanone with 2-aminopyridine gave 3-(4-methoxyphenyl)-2-pyridin-2-ylimidazo[1,2-a]pyridine, which was demethylated to afford phenol derivative The product inhibited TGF-β1-induced phosphorylation of Smad2/3.
IT 870990-98-0P 870990-99-1P
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridines as activin receptor-like kinase 5 inhibitors for treatment of TGF β-related diseases)
RN 870990-98-0 CAPLUS
CN Butanamide, N-[3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 870990-99-1 CAPLUS
CN Butanamide, N-[3-(4-hydroxyphenyl)-2-(2-pyridinyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



L3 ANSWER 16 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1220297 CAPLUS
DOCUMENT NUMBER: 143:460157
TITLE: Preparation of imidazopyridine derivatives as antagonists of melanin concentrating hormone receptor
INVENTOR(S): Sakuraba, Shunji; Moriya, Minoru; Takahashi, Hidekazu; Kishino, Hiroyuki; Jitsuoka, Makoto; Kameda, Minoru; Kanatani, Akio
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd, Japan
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005108399	A1	20051117	WO 2005-JP8819	20050509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005240942	A1	20051117	AU 2005-240942	20050509
CA 2566184	A1	20051117	CA 2005-2566184	20050509
EP 1748048	A1	20070131	EP 2005-739029	20050509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1950372	A	20070418	CN 2005-80015009	20050509
IN 2006DN06366	A	20070831	IN 2006-DN6366	20061030
US 20070249659	A1	20071025	US 2006-579570	20061106

PRIORITY APPLN. INFO.: JP 2004-139909 A 20040510
WO 2005-JP8819 W 20050509

OTHER SOURCE(S): MARPAT 143:460157
GI



I

AB Imidazopyridine compds. represented by the formula (I) [wherein R1 , R2 independently = H, halo, each (un)substituted C1- alkyl, C2-6 alkenyl, C3-8 cycloalkyl-C0-4 alkyl, C1-6 alkylamino di(C1-6 alkyl)amino, C1-6 alkylcarbonylamino, C1- alkylcarbonyl(C1-6 alkyl)amino, 3- to 8-membered heterocyclyl- C0- alkyl, or pyrazolyl-C1-4 alkyl; or R1 and R2 together

with the carbon atoms to which they are bonded, form 5- to 8-membered carbocyclic ring; R3 = H, halo, C1-6 alkyl, C1-6 alkyloxy; R4 = H C1-6 alkyl; W = (CH2)m+1, (CH2)mCH:CH(CH2)n, (CH2)m-O-(CH2)n, O-(CH2)m+1-O, (CH2)m-(O)y1-(CH2)n, (CH2)m-C(O)-(O)y2-(CH2)n, (CH2)m-CONH-(CH2)n, (CH2)m-NHCO-(CH2)n, or (CH2)m-NH-(CH2)n each optionally substituted in the alkylene group; m, n = an integer of 0-10, 0≤m+n≤10; y1 = 0, 1,2; y2 = 0, 1; Ar1 = a divalent substituent, e.g., (un)substituted mono- or bicyclic 3- to 8-membered aromatic or aliphatic heterocyclic or carbocyclic group; Ar2 = 5- to 6-membered aromatic carbocyclic or aromatic heterocyclic group] or pharmacol. acceptable salts thereof are prepared These compds. function as melanin-concentrating hormone (MCH) receptor antagonists and are useful as preventive or therapeutic agents for obesity, diabetes, hormone secretion disorder, gout, fatty liver, metabolic diseases represented by hepatitis or liver cirrhosis, angina pectoris, acute or ischemic heart failure, myocardial infarction, coronary arteriosclerosis, hypertension, Kidney disease, electrolyte abnormally represented by circulatory system disease, overeating, affective disorder, depression, anxiety, delirium, dementia, asyndesis, attention deficit hyperactivity disorder (ADHD), memory disorder, sleep disorder, cognition disorder, dyskinesia (movement disorder), sensory abnormality, olfaction disorder, morphine tolerance, central or peripheral neurol. diseases represented by drug dependence or alc. dependence, sterility, premature birth, sexual function disorders, digestive tract diseases, respiratory tract diseases, cancer, or skin pigmentation. Thus, a solution of 50 mg 2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-ylamine dihydrochloride in 1 mL DMF was treated with 50 mg 4-(6-chloropyridin-3-ylmethoxy)benzenecarboxylic acid, 79 mg HATU, and 232 μL diisopropylethylamine, stirred at room temperature for 2 h to give 4-(6-chloropyridin-3-ylmethoxy)-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)benzamide. N-[3-Methyl-2-(3-pyrrolidin-1-ylpropyl)imidazo[1,2-a]pyridin-6-yl]-4-[(E)-2-(pyridin-2-yl)ethenyl]benzamide showed IC50 of 0.47 nM against the binding of [125I]MCH to human MCH-1 receptor.

IT 869107-41-5P 869107-42-6P 869107-43-7P
869107-44-8P 869107-46-0P 869107-47-1P
869107-48-2P 869107-49-3P 869107-50-6P
869107-51-7P 869107-52-8P 869107-54-0P
869107-55-1P 869107-56-2P 869107-57-3P
869107-58-4P 869107-59-5P 869107-60-8P
869107-61-9P 869107-62-0P 869107-63-1P
869107-64-2P 869107-65-3P 869107-66-4P
869107-67-5P 869107-68-6P 869107-70-0P
869107-71-1P 869107-72-2P 869107-73-3P
869107-74-4P 869107-75-5P 869107-76-6P
869107-77-7P 869107-78-8P 869107-79-9P
869107-80-2P 869107-81-3P 869107-82-4P
869107-84-6P 869107-86-8P 869107-87-9P
869107-88-0P 869107-89-1P 869107-90-4P
869107-91-5P 869107-92-6P 869107-93-7P
869107-94-8P 869107-95-9P 869107-96-0P
869107-97-1P 869107-98-2P 869107-99-3P
869108-00-9P 869108-01-0P 869108-02-1P
869108-03-2P 869108-04-3P 869108-05-4P
869108-06-5P 869108-07-6P 869108-08-7P
869108-09-8P 869108-10-1P 869108-11-2P
869108-12-3P 869108-13-4P 869108-14-5P
869108-15-6P 869108-16-7P 869108-17-8P
869108-18-9P 869108-20-3P 869108-22-5P
869108-24-7P 869108-25-8P 869108-26-9P
869212-68-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of imidazopyridine derivs. as antagonists of melanin concentrating
hormone receptor)

RN 869107-41-5 CAPLUS
CN Benzamide, 4-[(6-chloro-3-pyridinyl)methoxy]-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 869107-42-6 CAPLUS
CN Benzamide, 4-[(5-chloro-2-pyridinyl)methoxy]-N-[3-methyl-2-[(1R,2R)-2-methylcyclopropyl]imidazo[1,2-a]pyridin-6-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 869107-43-7 CAPLUS
CN Benzamide, N-[2-(trans-3-methoxycyclobutyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 869107-44-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(phenylmethoxy)- (CA INDEX NAME)



RN 869107-46-0 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(phenylmethoxy)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 869107-45-9
CMF C25 H23 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 869107-47-1 CAPLUS
CN Benzamide, 4-[(5-fluoro-2-pyridinyl)methoxy]-N-[3-methyl-2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 869107-48-2 CAPLUS
CN Benzamide, 4-[(3-fluoro-2-pyridinyl)methoxy]-N-[3-methyl-2-(tetrahydro-3-furanyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 869107-49-3 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(6-fluoro-2-pyridinyl)methoxy]- (CA INDEX NAME)



RN 869107-50-6 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869107-51-7 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-2-fluoro-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869107-52-8 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-[(5-fluoro-2-pyridinyl)methoxy]- (CA INDEX NAME)



RN 869107-54-0 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(5-chloro-2-pyridinyl)methoxy]-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 869107-55-1 CAPLUS
CN Benzamide, N-[3-methyl-2-(1-pyrrolidinylmethyl)imidazo[1,2-a]pyridin-6-yl]-4-(phenylmethoxy)- (CA INDEX NAME)



RN 869107-56-2 CAPLUS
CN Benzamide, N-[2-(3-hydroxypropyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869107-57-3 CAPLUS
CN Benzamide, N-[2-[(1E)-3-hydroxy-1-propen-1-yl]-3-methylimidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-58-4 CAPLUS
CN Benzamide, N-[2-(3-hydroxy-3-methylbutyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869107-59-5 CAPLUS
CN Benzamide, N-[3-methyl-2-[3-(1-pyrrolidinyl)propyl]imidazo[1,2-a]pyridin-6-yl]-4-(phenylmethoxy)- (CA INDEX NAME)



RN 869107-60-8 CAPLUS
CN Benzamide, N-[3-methyl-2-[3-(1-pyrrolidinyl)propyl]imidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869107-61-9 CAPLUS
CN Benzamide, N-[2-[3-[(3S)-3-fluoro-1-pyrrolidinyl]propyl]-3-methylimidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 869107-62-0 CAPLUS
CN Benzamide, N-[2-[3-(3,3-difluoro-1-pyrrolidinyl)propyl]-3-methylimidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869107-63-1 CAPLUS
CN Benzamide, N-[3-methyl-2-[3-(4-morpholinyl)propyl]imidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869107-64-2 CAPLUS
CN Benzamide, N-[3-methyl-2-[3-(1H-pyrazol-1-yl)propyl]imidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869107-65-3 CAPLUS
CN Benzamide, N-[3-methyl-2-(tetrahydro-3-furanyl)imidazo[1,2-a]pyridin-6-yl]-4-[1-(2-pyridinyl)ethoxy]- (CA INDEX NAME)



RN 869107-66-4 CAPLUS
CN Benzamide, N-[3-methyl-2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]-4-[(5-methyl-1,3,4-thiadiazol-2-yl)methoxy]- (CA INDEX NAME)



RN 869107-67-5 CAPLUS
CN Benzamide, N-(2-cyclohexyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(2-pyridinyloxy)methyl]- (CA INDEX NAME)



RN 869107-68-6 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(5-fluoro-2-pyrimidinyl)hydroxymethyl]- (CA INDEX NAME)



RN 869107-70-0 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(1E)-2-phenylethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-71-1 CAPLUS
CN Benzamide, N-[3-methyl-2-(3-oxocyclobutyl)imidazo[1,2-a]pyridin-6-yl]-4-[(1E)-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-72-2 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(1E)-2-(6-methyl-2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-73-3 CAPLUS
CN Benzamide, 3-fluoro-N-[3-methyl-2-(tetrahydro-3-furanyl)imidazo[1,2-a]pyridin-6-yl]-4-[(1E)-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-74-4 CAPLUS
CN Benzamide, 4-[(1E)-2-(6-chloro-3-pyridinyl)ethenyl]-N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-75-5 CAPLUS
CN Benzamide, 4-[(1E)-2-(6-fluoro-2-pyridinyl)ethenyl]-N-[3-methyl-2-(tetrahydro-3-furanyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-76-6 CAPLUS
CN Benzamide, 4-[(1E)-2-(6-fluoro-2-pyridinyl)ethenyl]-N-[2-(1-hydroxy-1-methylethyl)-3-methylimidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-77-7 CAPLUS
CN Benzamide, 4-[(1E)-2-(5-fluoro-2-pyridinyl)ethenyl]-N-[3-methyl-2-(tetrahydro-3-furanyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-78-8 CAPLUS
CN Benzamide, 4-[(1E)-2-(5-fluoro-2-pyridinyl)ethenyl]-N-[2-(1-hydroxy-1-methylethyl)-3-methylimidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-79-9 CAPLUS
CN Benzamide, 4-[(1E)-2-(5-fluoro-2-pyridinyl)ethenyl]-N-[2-(methoxymethyl)-3-methylimidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-80-2 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(1E)-2-(2-thiazolyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-81-3 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(1Z)-2-fluoro-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-82-4 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(1Z)-1-fluoro-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-84-6 CAPLUS
CN Benzamide, 4-[(1Z)-1-fluoro-2-(2-pyridinyl)ethenyl]-N-[3-methyl-2-(tetrahydro-3-furanyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-86-8 CAPLUS
CN Benzamide, 4-[(1E)-1,2-difluoro-2-(2-pyridinyl)ethenyl]-N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-87-9 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(1E)-1-fluoro-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-88-0 CAPLUS
CN Benzamide, N-[2-(3-hydroxypropyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4-[(1E)-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-89-1 CAPLUS
CN Benzamide, N-[2-(3-hydroxy-3-methylbutyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4-[(1E)-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-90-4 CAPLUS
CN Benzamide, N-[3-methyl-2-(1-pyrrolidinylmethyl)imidazo[1,2-a]pyridin-6-yl]-4-[(1E)-2-phenylethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-91-5 CAPLUS
CN Benzamide, N-[3-methyl-2-[3-(1-pyrrolidinyl)propyl]imidazo[1,2-a]pyridin-6-yl]-4-[(1E)-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 869107-92-6 CAPLUS
CN Benzamide, N-[3-methyl-2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]-4-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 869107-93-7 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 869107-94-8 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(2-phenylethyl)- (CA INDEX NAME)



RN 869107-95-9 CAPLUS
CN 1,3,4-Thiadiazole-2-carboxamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(2-phenylethyl)- (CA INDEX NAME)



RN 869107-96-0 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[2-oxo-2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 869107-97-1 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[2-hydroxy-2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 869107-98-2 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[2-fluoro-2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 869107-99-3 CAPLUS
CN Benzamide, 4-[2,2-difluoro-2-(2-pyridinyl)ethyl]-N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 869108-00-9 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[1-hydroxy-2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 869108-01-0 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[1-fluoro-2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 869108-02-1 CAPLUS
CN Benzamide, N-[3-methyl-2-(tetrahydro-3-furanyl)imidazo[1,2-a]pyridin-6-yl]-4-[(2-pyridinylmethyl)thio]- (CA INDEX NAME)



RN 869108-03-2 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 869108-04-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[4-[[(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)amino]carbonyl]phenyl]- (CA INDEX NAME)



RN 869108-05-4 CAPLUS
CN Benzamide, N-[3-methyl-2-[(1R,2R)-2-methylcyclopropyl]imidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 869108-06-5 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(3-pyridinyloxy)- (CA INDEX NAME)



RN 869108-07-6 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(5-fluoro-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 869108-08-7 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(6-fluoro-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 869108-09-8 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[(3-fluoro-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 869108-10-1 CAPLUS
CN Benzamide, 4-[(4-chloro-2-pyridinyl)oxy]-N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 869108-11-2 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[[4-(methylthio)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 869108-12-3 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 869108-13-4 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[[3-(trifluoromethyl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 869108-14-5 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[[4-(trifluoromethyl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 869108-15-6 CAPLUS
CN Benzamide, 4-[(6-chloro-3-pyridazinyl)oxy]-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 869108-16-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-6-phenoxy- (CA INDEX NAME)



RN 869108-17-8 CAPLUS
CN 2-Pyrimidinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-phenoxy- (CA INDEX NAME)



RN 869108-18-9 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(phenylsulfonyl)- (CA INDEX NAME)



RN 869108-20-3 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(2-

phenylethoxy)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 869108-19-0
CMF C26 H25 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 869108-22-5 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(2-phenoxyethoxy)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 869108-21-4
CMF C26 H25 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 869108-24-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-

yl)-5-(2-pyridinylmethoxy)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 869108-23-6
CMF C26 H23 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 869108-25-8 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-1-(phenylmethyl)- (CA INDEX NAME)



RN 869108-26-9 CAPLUS
CN Benzamide, N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-[(2-pyridinyloxy)methyl]- (CA INDEX NAME)



RN 869212-68-0 CAPLUS
CN Benzamide, N-[2-(3-hydroxy-3-methylcyclobutyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4-[(1E)-2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 869109-57-9P 869109-67-1P 869109-70-6P
869109-71-7P 869109-72-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridine derivs. as antagonists of melanin concentrating
hormone receptor)

RN 869109-57-9 CAPLUS
CN 2-Propenoic acid, 3-[3-methyl-6-[[4-(2-pyridinylmethoxy)benzoyl]amino]imidazo[1,2-a]pyridin-2-yl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 869109-67-1 CAPLUS
CN Benzamide, N-[3-methyl-2-(3-oxopropyl)imidazo[1,2-a]pyridin-6-yl]-4-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 869109-70-6 CAPLUS
CN Imidazo[1,2-a]pyridine-2-propanoic acid, 3-methyl-6-[[4-[(1E)-2-(2-pyridinyl)ethenyl]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 869109-71-7 CAPLUS
CN Benzamide, N-[3-methyl-2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]-4-[2-(2-pyridinyl)ethenyl]- (CA INDEX NAME)



RN 869109-72-8 CAPLUS
CN Carbamic acid, [4-[[(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)amino]carbonyl]phenyl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:696877 CAPLUS
DOCUMENT NUMBER: 143:211847
TITLE: Preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity
INVENTOR(S): Potashman, Michele; Kim, Tae-Seong; Bellon, Steven; Booker, Shon; Cheng, Yuan; Kim, Joseph L.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Harmange, Jean-Christophe; Borg, George; Weiss, Matthew; Hodous, Brian L.; Graceffa, Russell; Buckner, Willian H.; Masse, Craig E.; Choquette, Deborah; Martin, Matthew W.; Germain, Julie; Dipietro, Lucian V.; Chaffee, Stuart C.; Nunes, Joseph J.; Buchanan, John L.; Habgood, Gregory J.; McGowan, David C.; Whittington, Douglas A.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 444 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005070891	A2	20050804	WO 2005-US2326		20050124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2005206571	A1	20050804	AU 2005-206571		20050124
CA 2553423	A1	20050804	CA 2005-2553423		20050124
EP 1713484	A2	20061025	EP 2005-722533		20050124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
US 20060241115	A1	20061026	US 2005-42634		20050124
US 7435823	B2	20081014			
CN 1933839	A	20070321	CN 2005-80006839		20050124
BR 2005007373	A	20070710	BR 2005-7373		20050124
JP 2007518824	T	20070712	JP 2006-551404		20050124
MX 2006PA08327	A	20060929	MX 2006-PA8327		20060721
IN 2006CN02683	A	20070608	IN 2006-CN2683		20060721
NO 2006003693	A	20061023	NO 2006-3693		20060817
PRIORITY APPLN. INFO.:			US 2004-538691P	P	20040123
			WO 2005-US2326	W	20050124

OTHER SOURCE(S): MARPAT 143:211847
GI



II

AB The title compds. I [R1XAYR; R = (un)substituted aryl, heterocyclyl, cycloalkyl, etc.; R1 = (un)substituted quinolinyl, quinazolinyl, pyrimidinyl, etc.; A = (un)substituted naphthalenediyl, etc.; X = O, S, (un)substituted NH, CH2; Y = NHCO, CONH, etc.] which are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases, were prepared E.g., a multi-step synthesis of II, starting from 6-hydroxy-2-naphthoic acid, was given. The compds. I showed inhibition of LcK kinase, c-Met kinase, and VEGFR kinase at less than 10 μM. The invention encompasses novel compds. I, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutically compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

IT 861874-98-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity)

RN 861874-98-8 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(1,1-dimethylethyl)imidazo[1,2-a]pyridin-6-yl]-6-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]- (CA INDEX NAME)



L3 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:158669 CAPLUS
DOCUMENT NUMBER: 142:261536
TITLE: Preparation of imidazopyridine derivatives as melanin-concentrating hormone receptor antagonists
INVENTOR(S): Kishino, Hiroyuki; Moriya, Minoru; Sakamoto, Toshihiro; Takahashi, Hidekazu; Sakuraba, Shunji; Suzuki, Takao; Kanatani, Akio
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016928	A1	20050224	WO 2004-JP11945	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004265189	A1	20050224	AU 2004-265189	20040813
CA 2535416	A1	20050224	CA 2004-2535416	20040813
EP 1657242	A1	20060517	EP 2004-771906	20040813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1835950	A	20060920	CN 2004-80023400	20040813
US 20080200494	A1	20080821	US 2006-567269	20060206
IN 2006DN00648	A	20070831	IN 2006-DN648	20060207
PRIORITY APPLN. INFO.:			JP 2003-207632 A	20030815
			WO 2004-JP11945 W	20040813

OTHER SOURCE(S): MARPAT 142:261536
GI



I



II

AB Title compds. I [R1, R2 = H, halo, etc., further detail on R1, R2 is given; R3 = H, halo, etc.; R4 = H, alkyl; W = single bond, etc.; Ar = optionally substituted aromatic ring, etc. with R7; R7 = halo, etc.] were prepared For example, Pd-catalyzed hydrogenation of 2-isopropyl-6-nitroimidazo[1,2-a]pyridine hydrobromide followed by HATU-mediated acylation with 4'-fluoro-1,1'-biphenyl-4-carboxylic acid afforded compound II. In MCH (Melanin Concentrating Hormone) binding inhibition assays, the IC50 value of compound II was 3.1 nM. Compds. I are claimed useful for the treatment of obesity, diabetes, etc.

IT 845826-07-5P 845826-38-2P 845826-50-8P 845826-64-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazopyridine derivs. as melanin-concentrating hormone receptor antagonists for treatment of obesity, diabetes, etc.)

RN 845826-07-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-38-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-(hydroxymethyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-50-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2-cyclopropylimidazo[1,2-a]pyridin-6-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-64-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methyl-2-(methylamin)imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



IT 845826-04-2P 845826-06-4P 845826-08-6P
845826-10-0P 845826-11-1P 845826-12-2P
845826-13-3P 845826-14-4P 845826-15-5P
845826-16-6P 845826-17-7P 845826-18-8P
845826-19-9P 845826-20-2P 845826-21-3P
845826-22-4P 845826-23-5P 845826-24-6P
845826-25-7P 845826-26-8P 845826-27-9P
845826-28-0P 845826-29-1P 845826-30-4P
845826-31-5P 845826-32-6P 845826-33-7P
845826-34-8P 845826-35-9P 845826-36-0P
845826-37-1P 845826-39-3P 845826-40-6P
845826-41-7P 845826-42-8P 845826-43-9P
845826-45-1P 845826-46-2P 845826-47-3P
845826-48-4P 845826-49-5P 845826-51-9P
845826-52-0P 845826-53-1P 845826-54-2P
845826-55-3P 845826-56-4P 845826-57-5P
845826-58-6P 845826-59-7P 845826-60-0P
845826-61-1P 845826-62-2P 845826-63-3P
845826-65-5P 845826-66-6P 845826-67-7P
845826-68-8P 845826-69-9P 845826-70-2P
845826-71-3P 845826-72-4P 845826-73-5P
845826-74-6P 845826-75-7P 845826-76-8P
845826-77-9P 845826-78-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as melanin-concentrating hormone receptor
antagonists for treatment of obesity, diabetes, etc.)
RN 845826-04-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-06-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 845826-08-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(3-methylimidazo[1,2-a]pyridin-6-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-10-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4'-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-11-1 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[5-(trifluoromethyl)-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-12-2 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[6-(trifluoromethyl)-3-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-13-3 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(6-fluoro-3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-14-4 CAPLUS
CN Benzamide, 4-(5-chloro-2-pyridinyl)-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 845826-15-5 CAPLUS
CN 2-Pyrimidinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(4-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-16-6 CAPLUS
CN 2-Pyrimidinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(3-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-17-7 CAPLUS
CN 2-Pyrazinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(4-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-18-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(4-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-19-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-6-(4-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845826-20-2 CAPLUS
CN Benzamide, N-[3-methyl-2-(tetrahydro-3-furanyl)imidazo[1,2-a]pyridin-6-yl]-4-[5-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 845826-21-3 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(2-pyridinyl)- (CA INDEX NAME)



RN 845826-22-4 CAPLUS
CN Benzenepropanamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-23-5 CAPLUS
CN 3-Pyridinepropanamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-6-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-24-6 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[5-(difluoromethoxy)-2-pyridinyl]- (CA INDEX NAME)



RN 845826-25-7 CAPLUS
CN [2,3'-Bipyridine]-6'-carboxamide, 5-chloro-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 845826-26-8 CAPLUS
CN 4-Piperidinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-1-(4-fluorophenyl)- (CA INDEX NAME)



RN 845826-27-9 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[6-

(difluoromethyl)-3-pyridinyl]- (CA INDEX NAME)



RN 845826-28-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-29-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4'-(methylsulfonyl)- (CA INDEX NAME)



RN 845826-30-4 CAPLUS
CN Benzamide, 4-(6-chloro-3-pyridazinyl)-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 845826-31-5 CAPLUS
CN [2,3'-Bipyridine]-6'-carboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 845826-32-6 CAPLUS
CN 2-Pyridinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(1H-pyrrol-1-yl)- (CA INDEX NAME)



RN 845826-33-7 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(5-methoxy-2-pyridinyl)- (CA INDEX NAME)



RN 845826-34-8 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 845826-35-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-36-0 CAPLUS
CN Benzamide, N-[2-(1-hydroxy-1-methylethyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4-[5-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 845826-37-1 CAPLUS
CN Benzamide, 4-(5-chloro-2-pyridinyl)-N-[2-(1-hydroxy-1-methylethyl)-3-methylimidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 845826-39-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-40-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-cyclopropyl-3-(hydroxymethyl)imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-41-7 CAPLUS
CN Benzamide, 4-(5-chloro-2-pyridinyl)-N-[2-cyclopropyl-3-(hydroxymethyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 845826-42-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methyl-2-[(2-oxo-1-pyrrolidinyl)methyl]imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-43-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[(acetylmethylamino)methyl]-3-methylimidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-45-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[(dimethylamino)methyl]-3-methylimidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 845826-44-0
CMF C25 H23 F3 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 845826-46-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-(acetylmethylamino)-3-

methylimidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-47-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-hydroxy- (CA INDEX NAME)



RN 845826-48-4 CAPLUS
CN Benzenepropanamide, N-[2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-49-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-(methoxymethyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-51-9 CAPLUS
CN Benzamide, N-[2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]-4-[5-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 845826-52-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2-methylimidazo[1,2-a]pyridin-6-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-53-1 CAPLUS
CN 1H-1,2,4-Triazole-3-carboxamide, 1-(4-fluorophenyl)-N-[2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 845826-54-2 CAPLUS
CN 2-Pyrimidinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 845826-55-3 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 845826-56-4 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-fluorophenyl)-N-[2-(1-methylethyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 845826-57-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[2-(1-hydroxyethyl)imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-58-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-(hydroxymethyl)imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-59-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[(acetylmethylamino)methyl]imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-60-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[(dimethylamino)methyl]imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-61-1 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)



RN 845826-62-2 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[2-(trifluoromethyl)-5-pyrimidinyl]- (CA INDEX NAME)



RN 845826-63-3 CAPLUS
CN 2-Pyrimidinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(2,4-difluorophenyl)- (CA INDEX NAME)



RN 845826-65-5 CAPLUS
CN 2-Pyrimidinecarboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-5-(6-fluoro-3-pyridinyl)- (CA INDEX NAME)



RN 845826-66-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2-cyclopropyl-3-ethylimidazo[1,2-a]pyridin-6-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-67-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methyl-2-[(2-oxo-1(2H)-pyridinyl)methyl]imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-68-8 CAPLUS
CN Acetamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-2-[4-(trifluoromethyl)phenoxy]- (CA INDEX NAME)



RN 845826-69-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-70-2 CAPLUS
CN Benzamide, N-(2-cyclopentyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(2-pyridinyl)- (CA INDEX NAME)



RN 845826-71-3 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[6-(dimethylamino)-3-pyridinyl]- (CA INDEX NAME)



RN 845826-72-4 CAPLUS
CN [2,3'-Bipyridine]-6'-carboxamide, 5-chloro-N-[2-cyclopropyl-3-

(methoxymethyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 845826-73-5 CAPLUS
CN Cyclohexanecarboxamide, 4-(5-chloro-2-pyridinyl)-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-hydroxy-, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 845826-74-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2-propylimidazo[1,2-a]pyridin-6-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845826-75-7 CAPLUS
CN Benzamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[5-(trifluoromethyl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 845826-76-8 CAPLUS
CN 1H-1,2,4-Triazole-3-carboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-1-(4-fluorophenyl)- (CA INDEX NAME)



RN 845826-77-9 CAPLUS
CN Cyclohexanecarboxamide, 4-(4-chlorophenyl)-N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



RN 845826-78-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-2-methyl-4'-(trifluoromethyl)- (CA INDEX NAME)



IT 845827-07-8P 845827-08-9P 845827-09-0P
845827-10-3P 845827-11-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridine derivs. as melanin-concentrating hormone receptor
antagonists for treatment of obesity, diabetes, etc.)

RN 845827-07-8 CAPLUS
CN Imidazo[1,2-a]pyridine-2-carboxylic acid, 6-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 845827-08-9 CAPLUS
CN Imidazo[1,2-a]pyridine-2-carboxylic acid, 3-methyl-6-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 845827-09-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-(chloromethyl)-3-methylimidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845827-10-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methyl-2-[methyl(2,2,2-trifluoroacetyl)amino]imidazo[1,2-a]pyridin-6-yl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 845827-11-4 CAPLUS
CN Carbamic acid, (2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-, phenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:60487 CAPLUS
DOCUMENT NUMBER: 140:111431
TITLE: Preparation of (2R,5S)-dimethylpiperazine derivatives for treatment of prostate cancer
INVENTOR(S): Taniguchi, Nobuaki; Imamura, Masakazu; Hayakawa, Masahiko; Kawaguchi, Kenichi; Kimura, Takenori; Kinoyama, Isao; Kaizawa, Hiroyuki; Okada, Minoru; Furutani, Takashi
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007471	A1	20040122	WO 2003-JP8860	20030711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492138	A1	20040122	CA 2003-2492138	20030711
AU 2003248052	A1	20040202	AU 2003-248052	20030711
EP 1557411	A1	20050727	EP 2003-764179	20030711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
IN 2005DN00006	A	20081107	IN 2005-DN6	20050103
US 20050261303	A1	20051124	US 2005-521119	20050112
US 7297698	B2	20071120		
US 20080214543	A1	20080904	US 2007-861327	20070926

PRIORITY APPLN. INFO.:

JP 2002-203690	A	20020712
WO 2003-JP8860	W	20030711
US 2005-521119	A3	20050112

GI



I



II

AB The title novel N-phenyl-(2R,5S)-dimethylpiperazine derivs. with general formula of I [wherein R1 = Cl, F, Br, CN, Me, CF3, or alkoxy; R2 = H, F, or MeO; R3 = H or alkyl; Cy = (un)substituted Ph, pyridyl, pyrimidinyl, imidazopyridinyl, benzopyrazinyl, quinoxalinyl, quinolinyl, benzothiazolyl, isoquinolinyl, benzothiadiazolyl, indolidinyl, or tetrahydrobenzofuranyl; with exclusions] or salts thereof are prepared For example, the compound II was prepared in a multi-step synthesis. II showed inhibitory activity with IC50 of 40 nM against transcription activation in rat. I are useful for the treatment of prostate cancer, prostate gland enlargement, etc.

IT 648422-85-9P 648423-14-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of dimethylpiperazine derivs. for treatment of prostate cancer)

RN 648422-85-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-cyano-3-fluoro-5-methoxyphenyl)-2,5-dimethyl-N-(2-methylimidazo[1,2-a]pyridin-6-yl)-, (2R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 648423-14-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-[4-cyano-3-(trifluoromethyl)phenyl]-N-imidazo[1,2-a]pyridin-6-yl-2,5-dimethyl-, hydrochloride (1:1), (2R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:20024 CAPLUS
DOCUMENT NUMBER: 140:87673
TITLE: Polymer-linked imidazopyridines useful as tumor-targeting cytotoxic agents
INVENTOR(S): Kasuya, Hiroshi; Miyazaki, Hideki; Hayakawa, Ichio; Kanno, Yuichi; Watanabe, Kazuyoshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 272 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004002826	A	20040108	JP 2003-115328	20030421
PRIORITY APPLN. INFO.:			JP 2002-121653 A	20020424

OTHER SOURCE(S): MARPAT 140:87673
GI



I

AB Claimed are polymer-linked imidazopyridines represented by POLYMER-LINKER-IPD, wherein POLYMER is selected from synthetic vinyl polymers, synthetic polypeptides, synthetic polyesters, polyethers, natural polymers, modified natural polymers, or block or graft copolymers comprising the polymers as constituent units; LINKER is selected from amino acids, peptides, and a single bond; and IPD indicates imidazopyridines I [R1 = R9X2; R9 = H, (substituted) alkyl, (substituted) cycloalkyl, (substituted) aryl, (substituted) heterocyclyl, (substituted) aralkyl, (substituted) arylalkenyl, carbamoyl; X2 = single bond, CO, OCO, NHCO, SO2; R2 = H; R3-R8 = halo, cyano, nitro, etc.; X1 = O, S, NH; excluding the compound where R1 = R2 = R3 = R5 = R6 = R7 = R8 = H, R4 = Me, and X1 = S], or their pharmacol. acceptable salts. (4-Methoxyphenyl)[4-(2-methylimidazo[1,2-α]pyridin-3-yl)thiazol-2-yl]amine showed cytotoxicity against HeLa, U-937, CaSKi, and HL-60 cells with ED50 of 1.8, 1.2, 1.6, and 20 ng/mL, resp. Mice bearing Lewis lung carcinoma were administered i.v. with polyethylene glycol Me 2-[N-[4-(6-chloro-2-methylimidazo[1,2-α]pyridin-3-yl)thiazol-2-yl]-N-(4-methoxyphenyl)carbamoylmethylaminocarbonyloxy]ethyl ether (preparation given) at 40 mg-imidazopyridine derivative/kg. The concns. of the imidazopyridine derivative in the tumor cells of the mice were 7.71 and 6.24 μg/mL 5 and 24 h after the i.v. administration, resp.

IT 420128-13-8P 420128-16-1P 420128-76-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of polymer-linked imidazopyridines for tumor-targeting cytotoxic agents)

RN 420128-13-8 CAPLUS
CN Carbamic acid, [4-[[3-[2-[acetyl(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 420128-16-1 CAPLUS
CN Carbamic acid, [4-[[3-[2-[(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 420128-76-3 CAPLUS
CN Butanamide, 4-amino-N-[3-[2-[(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]-, hydrochloride (1:4) (CA INDEX NAME)





L3 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:868091 CAPLUS
DOCUMENT NUMBER: 139:358739
TITLE: Pharmaceuticals containing imidazopyridines for prophylactic and therapeutic treatment of tumor
INVENTOR(S): Hayakawa, Ichio; Kanno, Yuichi; Azuma, Toshiki; Furukawa, Hidehiko; Naruto, Shunji; Kurakata, Shinichi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 148 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003313126	A	20031106	JP 2002-120000	20020423
PRIORITY APPLN. INFO.:			JP 2002-120000	20020423

OTHER SOURCE(S): MARPAT 139:358739
GI



I

AB Title pharmaceuticals contain imidazopyridines I [R1, R2 = R9X2; R9 = H, C1-6 (un)substituted alkyl, C3-8 (un)substituted cycloalkyl, (un)substituted aryl, etc.; X2 = bond, CO, O2C, NHCO, SO2; R3-R8 = halo, cyano, NO2, etc.] or their pharmacol. acceptable salts as active ingredients. Thus, refluxing 2-bromo-1-(2-methylimidazo[1,2-α]pyridin-3-yl)ethanone with (4-methoxyphenyl)thiourea gave (4-methoxyphenyl)[4-(2-methylimidazo[1,2-α]pyridin-3-yl)thiazol-2-yl]amine, which inhibited growth of HeLa cells with ED50 value of 1.8 ng/mg.

IT 420128-13-8P 420128-16-1P 420128-76-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridines as antitumor agents)

RN 420128-13-8 CAPLUS
CN Carbamic acid, [4-[[3-[2-[acetyl(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 420128-16-1 CAPLUS
CN Carbamic acid, [4-[[3-[2-[(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 420128-76-3 CAPLUS
CN Butanamide, 4-amino-N-[3-[2-[(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl

L3 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:5951 CAPLUS
DOCUMENT NUMBER: 138:73265
TITLE: Preparation of (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and cGMP-dependent protein kinase inhibiting compounds with therapeutic uses
INVENTOR(S): Biftu, Tesfaye; Colletti, Steven L.; Mcintyre, Charles J.; Schmatz, Dennis M.; Feng, Dennis D.; Doherty, James B.; Liang, Gui-Bai; Liverton, Nigel J.; Beresis, Richard; Berger, Richard; Claremon, David A.; Kovacs, Ernest W.; Qian, Xiaoxia
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 280 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000682	A1	20030103	WO 2002-US19507	20020621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450555	A1	20030103	CA 2002-2450555	20020621
AU 2002322273	A1	20030108	AU 2002-322273	20020621
US 20040176396	A1	20040909	US 2003-477367	20031112
US 7196095	B2	20070327		

PRIORITY APPLN. INFO.: US 2001-300748P P 20010625
WO 2002-US19507 W 20020621

OTHER SOURCE(S): MARPAT 138:73265
GI



I

AB (pyrimidyl)(phenyl)substituted fused heteroaryl compds. (shown as I; variables define below; e.g. (2-(4-fluorophenyl)-3-(2-[((S)-1-phenylethyl)amino]pyrimidin-4-yl)imidazo[1,2-a]pyridin-7-yl)methanol) and

pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis. I suppress TNF-α in monocytes and also IL-1β, IL-6 and PGE2 production with IC50 <5 μM. The 'Fused Het' in I may be optionally substituted radicals derived from imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrimidine, imidazo[2,1-b]thiazole, benzimidazole, etc. R1 is H, -C1-6alkyl, -C(O)(C1-6alkyl), -C(O)-C1-6-alkylaryl, -C0-4alkylaryl, -C0-4alkylindanyl, -C0-4alkylimidazolyl, -C0-4alkylthiazolyl, -C0-4alkylpyrazolyl, -C0-4alkyloxadiazolyl, -C0-4-alkyl-C3-6-cycloalkyl, -C0-4alkyl-C1-4-alkoxy, -C1-4-alkyl-N(C0-4-alkyl)(-C0-4-alkyl), -C1-4-alkyl-N(-C0-4alkyl)-CO-C1-4-alkoxy, -C1-4-alkylpiperidinyl, -C0-4alkyltriazolyl, -C1-4-alkylimidazothiazolyl, -C1-4-alkylbenzimidazolyl, -C1-4-alkylbenzothiazolyl, -C1-4-alkylbenzotetrahydrofuranyl, -C1-4-alkylbenzodioxolyl, -C1-4-alkyl-(heterocycloC4O2alkyl), -C1-4-alkyl-(heterocycloC5O1alkyl), -C1-4-alkyltetrahydrofuran, or -C1-4-alkyloxetanyl; R11 is H or -C1-6-alkyl; or R1 and R11, together with the N to which they are attached, form a morpholinyl; R2, R21, R22 each independently is H, halogen, or -C1-4alkyl;. Although the methods of preparation are not claimed, many example prepns. are included.

IT 480455-43-4P, Benzyl [2-(3-trifluoromethylphenyl)-3-[2-[((S)-1-phenylethyl)amino]pyrimidin-4-yl]imidazo[1,2-a]pyridin-6-yl]carbamate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and cGMP-dependent protein kinase inhibiting compds. with therapeutic uses)

RN 480455-43-4 CAPLUS

CN Carbamic acid, [3-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]imidazo[1,2-a]pyridin-6-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:408648 CAPLUS
DOCUMENT NUMBER: 137:6176
TITLE: Preparation of aromatic acid derivatives useful as serine protease inhibitors
INVENTOR(S): Bisacchi, Gregory S.; Sutton, James C., Jr.; Slusarchyk, William A.; Treuner, Uwe D.; Zhao, Guohua; Cheney, Daniel L.; Wu, Shung C.; Shi, Yan
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042273	A2	20020530	WO 2001-US46884	20011107
WO 2002042273	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2428191	A1	20020530	CA 2001-2428191	20011107
AU 2002027269	A	20020603	AU 2002-27269	20011107
EP 1332131	A2	20030806	EP 2001-996145	20011107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004514669	T	20040520	JP 2002-544409	20011107
HU 2004000651	A2	20040628	HU 2004-651	20011107

PRIORITY APPLN. INFO.: US 2000-246392P P 20001107
WO 2001-US46884 W 20011107

OTHER SOURCE(S): MARPAT 137:6176
GI



I



II

AB Aromatic compds. I, are useful as serine protease inhibitors, wherein ring B is Ph or pyridyl; W is amide, alkyl, alkenyl, heterocycle, heteroaryl, aryl, cycloalkyl; L is a linker group; X is N, CH, or C, provided that X is C when R1 and R2 join to form a fully unsatd. ring; Z is an optionally-substituted monocyclic or bicyclic ring system; R is H, alkoxy, amine, alkyl, alkenyl, halogen, haloalkyl, cyano, nitro, alkylthio, CHO, acyl, CO2H, alkoxycarbonyl, sulfonamido, sulfonyl, Ph; R1 and R2 (i) are independently selected from hydrogen, alkyl, alkenyl, heteroaryl, aryl, heterocycle, and cycloalkyl; or (ii) are taken together to form an aryl, heteroaryl, cycloalkyl, or heterocycle, provided that R1 and R2 do not together form pyrazole when W is methoxy and Z is biphenyl; and when R1 and R2 individually or together form a heteroaryl, aryl, heterocycle, cycloalkyl; R3 is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocycle, cycloalkyl, or alkyl substituted with -OC(O)R4 or -OC(O)OR4, wherein R4 is alkyl, cycloalkyl, provided that R3 is not Ph when W is methoxy. Thus, II was prepared for treating a coagulation-associated disorder, an inflammatory or immune disease, or metastases (no data). Included within the scope of the invention are pharmaceutical compns. for treating a serine protease disease, an inflammatory or immune condition, or cancer.

IT 431049-52-4P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic acid derivs. useful as anti-inflammatory, anticoagulant, antitumor, immunomodulator agents and serine protease inhibitors)

RN 431049-52-4 CAPLUS

CN Benzoic acid, 2-[2-[[(2-aminoimidazo[1,2-a]pyridin-6-yl)amino]carbonyl]-6-methoxy-3-pyridinyl]-5-[[(2,2-dimethylpropyl)amino]carbonyl]- (CA INDEX NAME)


OMe
N
O
C
NH
N
NH2
N
HO2C
C
NH
CH2
CMe3
O

L3 ANSWER 24 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:332191 CAPLUS
DOCUMENT NUMBER: 136:355236
TITLE: Preparation of imidazopyridine derivatives as antitumor agents
INVENTOR(S): Hayakawa, Ichiro; Sugano, Yuichi; Agatsuma, Toshinori; Furukawa, Hidehiko; Kurakata, Shinichi; Naruto, Shunji
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 371 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002034748	A1	20020502	WO 2001-JP9258		20011022
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
AU 2001095992	A5	20020506	AU 2001-95992		20011022
JP 2002255964	A	20020911	JP 2001-325843		20011024
PRIORITY APPLN. INFO.:			JP 2000-324043	A	20001024
			JP 2000-392331	A	20001225
			WO 2001-JP9258	W	20011022

OTHER SOURCE(S): MARPAT 136:355236
GI



I

AB The title compds. I [R1 represents substituted Ph, a substituted heterocycle, etc.; R2 represents hydrogen, aliphatic acyl, etc.; R3, R4, R5, R6, R7 and R8 represent each hydrogen, alkyl, halogeno, etc.; and X1 represents O, S, etc.] are prepared (4-Methoxyphenyl)-[4-(2-methylimidazo[1,2-α]pyridin-3-yl)thiazol-2-yl]amine showed ED50 of 1.8 ng/mL against Hela cells. Formulations are given.

IT 420128-16-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazopyridine derivs. as antitumor agents)

RN 420128-16-1 CAPLUS
CN Carbamic acid, [4-[[3-[2-[(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 420128-13-8P 420128-76-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as antitumor agents)

RN 420128-13-8 CAPLUS
CN Carbamic acid, [4-[[3-[2-[acetyl(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 420128-76-3 CAPLUS
CN Butanamide, 4-amino-N-[3-[2-[(6-methoxy-3-pyridinyl)amino]-4-thiazolyl]-2-methylimidazo[1,2-a]pyridin-6-yl]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:658147 CAPLUS
DOCUMENT NUMBER: 135:357881
TITLE: Heterocyclization of Functionalized Vinylic Derivatives of Imidazo[1,2-a]pyridines
AUTHOR(S): Chezal, Jean M.; Moreau, Emmanuel; Delmas, Gregory; Gueiffier, Alain; Blache, Yves; Grassy, Gerard; Lartigue, Claire; Chavignon, Olivier; Teulade, Jean C.
CORPORATE SOURCE: Faculte de Pharmacie, UMR INSERM 484 Universite d'Auvergne, Clermont-Ferrand, 63001, Fr.
SOURCE: Journal of Organic Chemistry (2001), 66(20), 6576-6584
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:357881
AB Heterocyclization of functionalized vinylic derivs. of imidazo[1,2-a]pyridines was explored exptl. and theor. using semiempirical AM1 and ab initio methods. A range of functionalized vinylic derivs. (azido, amino, and carbodiimide groups) were prepared for conversion into pyrroloazaindoles, imidazo[1,x]-, (x = 5, 6, 7, 8), [2,6]-, and [2,7]naphthyridines by thermal reaction. In the case of vinylic groups in the 5 position, peri annulation also was observed The exptl. and theor. data are compared and discussed.
IT 372147-98-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrroloazaindoles and naphthyridinoimidazoles by regioselective cyclization of vinyl azide-, amine- or heterocumulene-substituted imidazo[1,2-a]pyridines)
RN 372147-98-3 CAPLUS
CN Imidazo[1,2-a]pyridine-2-carboxylic acid, 6,6'-[[2-(ethoxycarbonyl)-3-oxo-1-propene-1,3-diyl]diimino]bis-, diethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 137 THERE ARE 137 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:167966 CAPLUS
DOCUMENT NUMBER: 134:207712
TITLE: Preparation of fused pyrrolecarboxamides as GABA brain receptor ligands
INVENTOR(S): Albaugh, Pamela; Shaw, Kenneth; Hutchison, Alan
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016103	A1	20010308	WO 2000-US23862	20000830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2381553	A1	20010308	CA 2000-2381553	20000830
BR 2000013664	A	20020514	BR 2000-13664	20000830
EP 1210328	A1	20020605	EP 2000-959643	20000830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200544	T2	20020621	TR 2002-544	20000830
HU 2002002534	A2	20021128	HU 2002-2534	20000830
HU 2002002534	A3	20021228		
JP 2003508385	T	20030304	JP 2001-519673	20000830
EE 200200111	A	20030616	EE 2002-111	20000830
IN 2002KN00184	A	20050311	IN 2002-KN184	20020205
MX 2002PA01709	A	20021023	MX 2002-PA1709	20020218
NO 2002000948	A	20020228	NO 2002-948	20020227
BG 106459	A	20021229	BG 2002-106459	20020228
PRIORITY APPLN. INFO.:			US 1999-151789P P	19990831
			US 1999-387311 A	19990831
			WO 2000-US23862 W	20000830

OTHER SOURCE(S): MARPAT 134:207712
GI



I

AB Substituted pyrrolecarboxamide compds. [I; T = halogen, hydrogen, hydroxy, amino, alkyl or alkoxy; X = hydrogen, hydroxy, amino, benzyl, tert-butoxycarbonyl, benzyloxycarbonyl, alkyl, or alkoxy; G = -Q-(CH2)k-W-(CH2)m-Z; where Q = an optionally substituted aryl or optionally substituted heteroaryl group having from 1 to 3 rings, 3 to 8

members in each ring and from 1 to 3 heteroatoms; W = hydrogen, O, NH, NR7, S(O)0-2,CO, OC(O), C(O)O, C(O)NH, NHC(O), NR7C(O), NHS(O)0-2, NR7S(O)0-2, S(O)0-2NH, S(O)0-2NR7, and CR7R8; where R7, R8 = hydrogen or alkyl, or CR7R8 = a cyclic moiety having 3-7 carbon atoms; Z = hydrogen, hydroxy, cycloalkyl(alkoxy), amino, mono- or di(alkyl)amino, azacycloalkyl, O(alkyl), S(O)0-2(alkyl), C(O)(alkyl), OC(O)(alkyl), OC(O)H, C(O)O(alkyl), C(O)OH, C(O)NH(alkyl), etc.; R3, R4, R5, R6 = hydrogen, alkyl, COR11 or CO2R11 (where R11 = alkyl or cycloalkyl having 3-7 carbon atoms), CONR12R13 (where R12, R13 = hydrogen, alkyl, cycloalkyl having 3-7 carbon atoms, Ph, 2-, 3-, or 4-pyridyl, or NR12R13 forms a heterocyclic group), etc.; or R3 and R4 together with the carbon atom to which they are attached form a cyclic moiety having 3-7 carbon atoms] are disclosed. These compds. are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compns., including packaged pharmaceutical compns., are further provided. Compds. of the invention are also useful as probes for the localization of GABAA receptors in tissue samples. Thus, To a stirred solution of 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (100 mg, 0.6 mmol) and Et3N (0.15 mL, 1.1 mmol) in DMF (5 mL) at 0° is added Et chloroformate (0.1 mL, 1.1 mmol), stirred for 1 h, treated with 3-[N-trifluoroacetyl(methylaminomethyl)]aniline (0.3 g, 1.3 mmol), and the reaction mixture was stirred for 4 h to give, after workup, N-[3-(methylaminomethyl)phenyl]-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide (II). II and N-[4-(2-methylaminoethyl)phenyl]-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide showed binding affinity for GABAA receptor with Ki of 90 and 0.24, resp., in a binding assay described by Thomas and Tallman (J. Bio. Chemical 1981 and J. Neurosci. 1983).

IT 329018-52-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused pyrrolecarboxamides as GABA brain receptor ligands for treatment of central nervous system diseases)

RN 329018-52-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-imidazo[1,2-a]pyridin-6-yl-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:184253 CAPLUS
DOCUMENT NUMBER: 130:223263
TITLE: Preparation and bactericidal activity of [(aminomethyl)oxooxazolidinyl]benzene derivatives
INVENTOR(S): Mills, Stuart Dennett
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911642	A1	19990311	WO 1998-GB2556	19980825
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9888721	A	19990322	AU 1998-88721	19980825
EP 1007525	A1	20000614	EP 1998-940384	19980825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514259	T	20010911	JP 2000-508681	19980825
ZA 9807861	A	19990301	ZA 1998-7861	19980828
US 6362191	B1	20020326	US 2000-485972	20000218

PRIORITY APPLN. INFO.: GB 1997-18208 A 19970829
GB 1997-27160 A 19971224
WO 1998-GB2556 W 19980825

OTHER SOURCE(S): MARPAT 130:223263
GI



AB The title compds. I [A = 5-membered heteroaryl ring, bicyclic benzo system containing 5-membered heteroaryl ring, bicyclic or tricyclic heteroaryl ring system with at least one bridgehead nitrogen and optionally a further 1-3 heteroatoms chosen from oxygen, sulfur and nitrogen; R1 = OH, halo, amino, nitro, cyano, carboxy, thiol, C1-4alkanoyloxy, C1-4alkoxycarbonyl, dimethylaminomethyleneaminocarbonyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, optionally substituted Ph, an optionally substituted 5- or 6-membered heteroaryl ring or hydroxyC1-4alkyl; n = 0-6; R2, R3 = H, F; R4 = C1-4alkyl], useful as antibacterial agents against gram-pos. pathogens, were prepared E.g., N-([(5S)-N-(4-[imidazol-2-ylcarbonyl]phenyl)-2-oxooxazolidin-5-yl]methyl)acetamide was prepared

IT 221185-03-1P 221185-07-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and bactericidal activity of [(aminomethyl)oxooxazolidinyl]benzene derivs.)

RN 221185-03-1 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[[6-(acetylamino)imidazo[1,2-a]pyridin-3-yl]carbonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 221185-07-5 CAPLUS

CN Acetamide, N-[3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]benzoyl]imidazo[1,2-a]pyridin-6-yl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



IT 221185-55-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bactericidal activity of [(aminomethyl)oxooxazolidinyl]benzene derivs.)

RN 221185-55-3 CAPLUS

CN Acetamide, N-[3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]benzoyl]imidazo[1,2-a]pyridin-6-yl]-2-(acetyloxy)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:553526 CAPLUS
DOCUMENT NUMBER: 119:153526
ORIGINAL REFERENCE NO.: 119:27349a,27352a
TITLE: Carbamate derivatives of 2-arylimidazo[1,2-a]pyridinium salts as acetylcholinesterase inhibitors and protective agents against organophosphorus compounds
AUTHOR(S): Sundberg, Richard J.; Dalvie, Deepak; Cordero, Joehassin; Musallam, H. A.
CORPORATE SOURCE: Dep. Chem., Univ. Virginia, Charlottesville, VA, 22901, USA
SOURCE: Chemical Research in Toxicology (1993), 6(4), 506-10
CODEN: CRTOEC; ISSN: 0893-228X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of 2-arylimidazo[1,2-a]pyridinium salts with (N,N-dimethylcarbamoyl)oxy or (N-methylcarbamoyl)oxy groups at the 3'- or 4'-position on the Ph substituent and various substituents on the imidazo[1,2-a]pyridine ring have been synthesized (e.g. I). The compds. show in vitro inhibitory activity against elec. eel acetylcholinesterase (AChE), type III, and several of the compds. show protective effects toward the organophosphorus AChE inhibitor soman in mice. The possible structural relationship of these compds. to physostigmine and pyridostigmine is considered.

IT 149964-91-0P, BM 04364 149964-92-1P, BL 55142
149964-93-2P, BM 05567 149964-95-4P, BM 04926
149964-96-5P, BM 04935 149964-97-6P, BM 04346
149965-06-0P, BM 03689 149965-11-7P, BM 03670
149965-13-9P, BM 03189 149965-15-1P, BM 07650
150086-29-6P, BM 03198
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antidotal activity of)

RN 149964-91-0 CAPLUS

CN Imidazo[1,2-a]pyridinium, 2-[4-[[(dimethylamino)carbonyl]oxy]phenyl]-6-(formylamino)-1-methyl-, chloride (1:1) (CA INDEX NAME)



RN 149964-92-1 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-(acetylamino)-2-[4-[[(dimethylamino)carbonyl]oxy]phenyl]-1-methyl-, chloride (1:1) (CA INDEX NAME)





RN 149964-93-2 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-(acetylmethylamino)-2-[4-[[(dimethylamino)carbonyl]oxy]phenyl]-1-methyl-, chloride (1:1) (CA INDEX NAME)





RN 149964-95-4 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-(benzoylamino)-2-[4-[[(dimethylamino)carbonyl]oxy]phenyl]-1-methyl-, chloride (1:1) (CA INDEX NAME)



RN 149964-96-5 CAPLUS
CN Imidazo[1,2-a]pyridinium, 2-[4-[[(dimethylamino)carbonyl]oxy]phenyl]-1-methyl-6-[[(methylamino)carbonyl]amino]-, chloride (1:1) (CA INDEX NAME)



RN 149964-97-6 CAPLUS
CN Imidazo[1,2-a]pyridinium, 2-[4-[[(dimethylamino)carbonyl]oxy]phenyl]-6-[(methoxycarbonyl)amino]-1-methyl-, chloride (9CI) (CA INDEX NAME)



RN 149965-06-0 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-(acetylamino)-2-[3-[[(dimethylamino)carbonyl]oxy]phenyl]-1-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 149965-05-9
CMF C19 H21 N4 O3



CM 2

CRN 16722-51-3
CMF C7 H7 O3 S



RN 149965-11-7 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-(acetylamino)-1-methyl-2-[3-[[(methylamino)carbonyl]oxy]phenyl]-, iodide (1:1) (CA INDEX NAME)





RN 149965-13-9 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-(acetylamino)-1-methyl-2-phenyl-, iodide (1:1) (CA INDEX NAME)



RN 149965-15-1 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-[(methoxycarbonyl)amino]-1-methyl-2-phenyl-,

chloride (1:1) (CA INDEX NAME)





RN 150086-29-6 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-(acetylamino)-1-methyl-2-[4-
[[(methylamino)carbonyl]oxy]phenyl]-, iodide (1:1) (CA INDEX NAME)





L3 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:661569 CAPLUS
DOCUMENT NUMBER: 117:261569
ORIGINAL REFERENCE NO.: 117:45065a,45068a
TITLE: Silver halide color photographic material
INVENTOR(S): Yamakawa, Kazuyoshi; Ishii, Yoshio
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04191736	A	19920710	JP 1990-321022	19901127
PRIORITY APPLN. INFO.:			JP 1990-321022	19901127

GI



I

AB In the title material comprising a support having thereon one or more Ag halide emulsion layers, at least one of the Ag halide emulsion layers contains a cyan coupler represented by I (Z, T = CR, N; R = H, a substituent group; Y = nonmetallic atoms for forming a 5-membered N-containing heterocyclic ring; X = H, a group to be released upon coupling reaction with an oxidized color developing agent). The title material gives excellent color reproduction

IT 144762-24-3 144762-25-4
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler)

RN 144762-24-3 CAPLUS
CN Butanamide, N-[6-(acetylamino)-5-chloro-8-hydroxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-7-yl]-2-[2,4-bis(1,1-dimethylpropyl)phenoxy]- (CA INDEX NAME)



RN 144762-25-4 CAPLUS
CN Octanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-(5-chloro-7-cyano-8-hydroxy-2-methylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)


Me
Et
C
Me
Me
(CH2)5
O
CH
C
NH
O
OH
NC
N
Me
N
Et
C
Me
Me
Cl

L3 ANSWER 30 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:661567 CAPLUS
DOCUMENT NUMBER: 117:261567
ORIGINAL REFERENCE NO.: 117:45065a,45068a
TITLE: Silver halide color photographic material
INVENTOR(S): Yamakawa, Kazuyoshi; Ishii, Yoshio
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04190232	A	19920708	JP 1990-317882	19901126

PRIORITY APPLN. INFO.: JP 1990-317882 19901126
GI



I

AB The title material contains a cyan coupler represented by general structure I (R1 = H, a substituent group; Z = CR2, N; R2 = H, a substituent group; Y = nonmetallic atoms for forming a N-containing 5-membered heterocyclic ring; X = H, a group to be released upon reaction with an oxidized color developing agent; R1 and R2 or R2 and X may form a 5- to 7-membered ring). The title material shows high sensitivity.
IT 144762-00-5
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 144762-00-5 CAPLUS
CN Acetamide, N-[7-(acetylamino)-5-hydroxy-8-(2-hydroxyethoxy)-2,3-bis(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-2-[2,4-bis(1,1-dimethylpropyl)phenoxy]- (CA INDEX NAME)



L3 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:101827 CAPLUS
DOCUMENT NUMBER: 114:101827
ORIGINAL REFERENCE NO.: 114:17357a,17360a
TITLE: Synthesis of 1H-imidazo[1,2-a]pyrazolo[3,4-c]pyridines
AUTHOR(S): Gueiffier, Alain; Milhavet, Jean Claude; Blache, Yves; Chavignon, Olivier; Teulade, Jean Claude; Madesclaire, Michel; Viols, Henry; Dauphin, Gerard; Chapat, Jean Pierre
CORPORATE SOURCE: Lab. Chim. Org. Pharm., Fac. Pharm., Montpellier, 34060, Fr.
SOURCE: Chemical & Pharmaceutical Bulletin (1990), 38(9), 2352-6
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:101827
GI


I


II

AB The reaction of nitrosyl chloride with 6- and 8-acetamido-7-methylimidazo[1,2-a]pyridines I (R1 = R3 = H, R2 = NHAc, R4 = Ph, CO2Et; R1 = NHAc, R2 = R3 = H, R4 = CO2Et) reveal clear differences of reactivity of these isomeric structures. After bifunctionalization of the imidazolic moiety, the 6-acetamido derivs. do not yield the 1H-imidazo[1,2-a]pyrazolo[4,5-d]pyridine system, but undergo a Gomberg-Bachman reaction complicated by Dimroth rearrangement. In contrast, upon similar treatment, the 8-acetamido compds. I (R1 = NHAc, R2 = H, R3 = Br, NO2; R4 = CO2Et) yielded the N-nitrosoacetamides I [R1 = N(NO)Ac], which were converted into 1H-imidazo[1,2-a]pyrazolo[3,4-c]pyridines II (R3 = Br, NO2) in 22 and 34% yields, resp., without rearrangement.
IT 132272-57-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and attempted N-nitrosation of, with nitrosyl chloride)
RN 132272-57-2 CAPLUS
CN Acetamide, N-(7-methyl-2-phenylimidazo[1,2-a]pyridin-6-yl)- (CA INDEX NAME)



L3 ANSWER 32 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:30227 CAPLUS
DOCUMENT NUMBER: 112:30227
ORIGINAL REFERENCE NO.: 112:5065a,5068a
TITLE: Cationic antiprotozoal drugs. Trypanocidal activity of 2-(4'-formylphenyl)imidazo[1,2-a]pyridinium guanylhydrazones and related derivatives of quaternary heteroaromatic compounds
AUTHOR(S): Sundberg, Richard J.; Dahlhausen, Daniel J.; Manikumar, G.; Mavunkel, B.; Biswas, A.; Srinivasan, V.; Musallam, H. A.; Reid, Willis A., Jr.; Ager, Arba L.
CORPORATE SOURCE: Dep. Chem., Univ. Virginia, Charlottesville, VA, 22901, USA
SOURCE: Journal of Medicinal Chemistry (1990), 33(1), 298-307
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of quaternary 2-phenylimidazo[1,2-a]pyridinium salts were prepared and evaluated for antiparasitic activity. Primary attention was focused on derivs. with amido, substituted hydrazone, and heterocyclic functionality at the para-position of the Ph substituent. Guanylhydrazones and N-substituted guanylhydrazones of the 4'-formyl-substituted compds. were very active against the blood state Trypanosoma rhodesiense in mice by s.c. or oral administration. The most potent compds. caused 100% survival for 30 days at <1.0 mg/kg, s.c., and >5.0 mg/kg, orally. Weaker activity was noted for certain other 4'-substituents such as carboxamidines and carboxamide oximes. Considerable variation in structure, including replacement of the imidazo[1,2-a]pyridinium ring by other cationic heterocyclic rings and insertion of linking groups between the heterocyclic ring and Ph group, could be done, and a high level of activity was maintained. Relationships between these structural changes and biol. activity are discussed.
IT 123509-32-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and trypanosomicidal activity of, structure in relation to)
RN 123509-32-0 CAPLUS
CN Imidazo[1,2-a]pyridinium, 6-(acetylamino)-2-[4-[[2-(aminoiminomethyl)hydrazinylidene]methyl]phenyl]-1-methyl-, compd. with 4-methylbenzenesulfonate, 4-methylbenzenesulfonate (1:1:1) (CA INDEX NAME)

CM 1

CRN 104-15-4
CMF C7 H8 O3 S



CM 2

CRN 123509-31-9
CMF C18 H20 N7 O . C7 H7 O3 S

CM 3

CRN 123509-30-8
CMF C18 H20 N7 O



CM 4

CRN 16722-51-3
CMF C7 H7 O3 S



L3 ANSWER 33 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:553802 CAPLUS
DOCUMENT NUMBER: 111:153802
ORIGINAL REFERENCE NO.: 111:25653a,25656a
TITLE: Imidazopyridine derivatives for the treatment of ulcers, a process for their preparation, and their pharmaceutical compositions
INVENTOR(S): Shiokawa, Youichi; Nagano, Masanobu; Itani, Hiromichi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 308917	A2	19890329	EP 1988-115541	19880922
EP 308917	A3	19900711		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8806831	A	19890530	ZA 1988-6831	19880913
FI 8804318	A	19890325	FI 1988-4318	19880921
JP 01151579	A	19890614	JP 1988-238522	19880922
US 4920129	A	19900424	US 1988-247657	19880922
DK 8805320	A	19890325	DK 1988-5320	19880923
NO 8804231	A	19890328	NO 1988-4231	19880923
AU 8822783	A	19890406	AU 1988-22783	19880923
HU 48245	A2	19890529	HU 1988-4996	19880923
HU 201934	B	19910128		
CN 1033628	A	19890705	CN 1988-106859	19880923

PRIORITY APPLN. INFO.: GB 1987-22488 A 19870924
OTHER SOURCE(S): MARPAT 111:153802
GI



I



II

AB Title compds. I [R1 = alkynyl; R2, R3 = alkyl; R4 = (protected) amino; R5 = H, halo, NO2, protected CO2H, (protected) amino, (substituted) alkyl, N,N-dialkylsulfamoyl; A = alkylene] are prepared for use in therapy of ulcers. Cyclocondensation of 2,3-diaminopyridine with 3-mesyloxy-5-hexyn-2-one in refluxing MeOH gave 8-amino-3-(2-propynyl)-2-methylimidazo[1,2-a]pyridine, which was alkylated by 2,6-Me(MeO2CNH)C6H3CH2Cl and Et3N in MeOH to give II. At 3.2 mg/kg orally in dogs with Heidenhain pouches, II completely inhibited gastric acid secretion induced by i.v. gastrin (10 μg/kg/h).

IT 122771-54-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as ulcer inhibitor)

RN 122771-54-4 CAPLUS

CN Carbamic acid, [2-[[[6-(acetylamino)-2-methyl-3-(2-propynyl)imidazo[1,2-a]pyridin-8-yl]amino]methyl]-3-methylphenyl]-, methyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 34 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:23789 CAPLUS
DOCUMENT NUMBER: 110:23789
ORIGINAL REFERENCE NO.: 110:4021a,4024a
TITLE: Preparation of 2-aryl- and 2-(aryloxymethyl)imidazo[1,2-a]pyridines and related compounds
AUTHOR(S): Sundberg, Richard J.; Dahlhausen, D. J.; Manikumar, G.; Mavunkel, B.; Biswas, Atanu; Srinivasan, V.; King, Fred, Jr.; Waid, Philip
CORPORATE SOURCE: Dep. Chem., Univ. Virginia, Charlottesville, VA, 22901, USA
SOURCE: Journal of Heterocyclic Chemistry (1988), 25(1), 129-37
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:23789
GI



I



III



IV

AB A series of arylimidazopyridines I (R = H, R1 = H, 6-Me, 7-Me, 6-NO2, 6-Cl, 6-iodo, 6-OMe, 6-SEt, 6-SPr; R2 = Br, NO2) were prepared by the cyclocondensation of 2-aminopyridines with 4-R2C6H4COCH2Br (II). I (R = H, R1 = 6-NHAc, 6-SOEt, 6-SO2Et, 6-cyano- 6-CHO, R2 = NHAc, NHSO2Me, NHSO2Ph, cyano, CHO, CO2Me, CONH2, CSNH2; R = Br, cyano, CHO, R1 = H, R2 = Me, Br, NO2) were also prepared Imidazolthiazoles III and imidazopyrimidines IV (R2 = NO2, NHAc, iodo, cyano, CHO) were prepared by the reactions of 2-aminothiazoles and 2-aminopyrimidine resp. with II (R2 = Br, NO2, iodo). Various other heterocyclic compds., e.g., 4-R3CH2OC6H4CHO (R3 = 1-methylimidezol-2-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-thiazolyl, etc.), were prepared by condensation reactions.

IT 118000-60-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion to aldehyde)

RN 118000-60-5 CAPLUS
CN Acetamide, N-[2-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



IT 118000-59-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation and cyanation of)
RN 118000-59-2 CAPLUS
CN Acetamide, N-[2-(4-bromophenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



IT 118000-58-1P 118000-61-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 118000-58-1 CAPLUS
CN Acetamide, N-[4-[6-(acetylamino)imidazo[1,2-a]pyridin-2-yl]phenyl]- (CA INDEX NAME)



RN 118000-61-6 CAPLUS
CN Acetamide, N-[2-(4-formylphenyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



L3 ANSWER 35 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:569072 CAPLUS
DOCUMENT NUMBER: 95:169072
ORIGINAL REFERENCE NO.: 95:28261a,28264a
TITLE: Imidazo[1,2-a]pyridine anthelmintics. Synthesis of 6-phenylaminoimidazo[1,2-a]pyridine-2-carbamate and 5-acylaminopyridines by a Chapman rearrangement
AUTHOR(S): Peterson, L. H.; Douglas, A. W.; Tolman, R. L.
CORPORATE SOURCE: Merck Sharp and Dohme Res. Lab., Rahway, NJ, 07065, USA
SOURCE: Journal of Heterocyclic Chemistry (1981), 18(4), 659-62
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 95:169072
GI



I

AB The title compound (I) a potential anthelmintic agent, was prepared in seven steps from 5-hydroxy-2-picoline. The intermediate 5-(N-phenylbenzamido)-2-picoline was prepared by a facile Chapman rearrangement of the corresponding benzimidoyl ester. Oxidation and Curtius rearrangement of the substituted picoline gave 5-(N-phenylbenzamido)-2-aminopyridine which underwent ring closure and debenzoylation to furnish I. Fries rearrangement of the penultimate N-benzoyl derivative gave a 6-(p-benzoylphenylamino)imidazo[1,2-a]pyridine derivative, whose structure was confirmed by NMR study. I lacked significant anthelmintic activity.

IT 79441-23-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 79441-23-9 CAPLUS

CN Carbamic acid, [6-(benzoylphenylamino)imidazo[1,2-a]pyridin-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 36 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:43479 CAPLUS
DOCUMENT NUMBER: 78:43479
ORIGINAL REFERENCE NO.: 78:6879a,6882a
TITLE: Imidazo[1,2-a]pyridines
INVENTOR(S): Fisher, Michael H.
PATENT ASSIGNEE(S): Merck and Co., Inc.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3701780	A	19721031	US 1970-73603	19700918
GB 1353370	A	19740515	GB 1971-42581	19710913
AU 7133578	A	19730322	AU 1971-33578	19710916
ZA 7106205	A	19730425	ZA 1971-6205	19710916

PRIORITY APPLN. INFO.: US 1970-73603 A 19700918
GI For diagram(s), see printed CA Issue.
AB Imidazo [1,2-a]pyridines I, useful as fungicides and anthelmintics, were prepared Thus I (R = 4-thiazolyl, R1 = H) was prepared via a Grignard reaction of 4-cyanothiazole; bromination of the resulting 4-acetylthiazole and cyclization of the 4-(bromoacetyl)thiazole with 2-aminopyridine. Alternately, I (R = NHCO2Me; R1 = Me) was prepared in 4 steps from ClCH2CONH2 and 2-(p-aminobenzene-sulfonamido)-5-methylpyridine. About 27 I (e.g. R = C.tplbond.N, CONH2, NH2; R4 = NH2, NO2, Me) were also prepared
IT 36911-63-4 38923-01-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)
RN 36911-63-4 CAPLUS
CN Carbamic acid, [2-(4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 38923-01-2 CAPLUS
CN Carbamic acid, [2-(4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)



IT 36911-64-5P 38923-06-7P 38923-11-4P
38923-12-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36911-64-5 CAPLUS
CN Carbamic acid, [2-(4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, 1-methylethyl

ester (9CI) (CA INDEX NAME)



RN 38923-06-7 CAPLUS
CN Benzamide, N-[2-(4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 38923-11-4 CAPLUS
CN Carbamic acid, [2-(3-oxido-4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-,
methyl ester (9CI) (CA INDEX NAME)



RN 38923-12-5 CAPLUS
CN Carbamic acid, [2-(3-oxido-4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, ethyl
ester (9CI) (CA INDEX NAME)



L3 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:547658 CAPLUS
DOCUMENT NUMBER: 77:147658
ORIGINAL REFERENCE NO.: 77:24235a,24238a
TITLE: Imidazo[1,2-a]pyridine anthelmintic and antifungal agents
AUTHOR(S): Fisher, Michael H.; Lusi, Aino
CORPORATE SOURCE: Merck Sharp and Dohme Res. Lab., Div., Merck and Co., Inc., Rahway, NJ, USA
SOURCE: Journal of Medicinal Chemistry (1972), 15(9), 982-5
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Derivs. of 2-(4-thiazolyl)imidazo[1,2-a]pyridine, in which the 6 position was protected from inactivation by enzymic hydroxylation by means of acylamino substitution, showed antifungal activity in vitro and anthelmintic activity in vitro and in vivo; the 2 types of activity were not well correlated. 6-(Ethoxycarbonyl)amino-2-(4-thiazolyl)imidazo[1,2-a]pyridine (I) [36911-63-4] was active in vitro against trichostrongyles at 100 μg/ml and was active in vivo against a broad spectrum of helminths in sheep at 25 mg/kg orally. 6-(Isopropoxycarbonyl)amino-2-(4-thiazolyl)imidazo[1,2-a]pyridine [36911-64-5] was active at .geq.10 ppm against Aspergillus niger, Pullularia pullulans, and Penicillium luteum. To synthesize I, 4-cyanothiazole was converted with MeMgI to 4-acetylthiazole, with Br to 4-bromoacetylthiazole, and reacted with 2,5-diaminopyridine to yield 6-amino-2-(4-thiazolyl)imidazo[1,2-a]pyridine, which was reacted with Et chloroformate to yield I.

IT 36911-63-4 36911-64-5 38923-01-2
38923-06-7 38923-11-4 38923-12-5
RL: BIOL (Biological study)
(anthelmintic and fungicidal activity of)

RN 36911-63-4 CAPLUS
CN Carbamic acid, [2-(4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 36911-64-5 CAPLUS
CN Carbamic acid, [2-(4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 38923-01-2 CAPLUS
CN Carbamic acid, [2-(4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 38923-06-7 CAPLUS
CN Benzamide, N-[2-(4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]- (CA INDEX NAME)



RN 38923-11-4 CAPLUS
CN Carbamic acid, [2-(3-oxido-4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 38923-12-5 CAPLUS
CN Carbamic acid, [2-(3-oxido-4-thiazolyl)imidazo[1,2-a]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 38 OF 38 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1950:22578 CAPLUS
DOCUMENT NUMBER: 44:22578
ORIGINAL REFERENCE NO.: 44:4474g-i,4475a-b
TITLE: Syntheses of heterocyclic compounds of nitrogen. XLIX. Pyrimidazoles
AUTHOR(S): Takahashi, Torizo; Shibasaki, Juichiro
CORPORATE SOURCE: Univ. Kyoto
SOURCE: Yakugaku Zasshi (1949), 69, 496-7
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C.A. 44, 1977f. Heating 4 g. 2-amino-5-nitropyridine, 40 ml. H2O, and 8 g. EtOCHClCH2Cl on a sand bath for 4 hrs., neutralization with aqueous Na2CO3, filtration of the precipitate, and recrystn. from MeOH gives 1.7 g. 5-nitropyrimidazole (I), yellow prisms, m. 225°. Heating 1.5 g. I, 60 g. 35% HCl, and 3.7 g. Sn on a sand bath, drying in vacuo, taking up with 200 ml. H2O, passing in H2S, removing the SnS, and concentrating the filtrate in vacuo gives 1 g. 5-aminopyrimidazole-HCl (II). Extraction of 1 g. II in 20% NaOH solution with ether gives 0.6 g. sirup; addition of 0.8 g. BzCl, stirring with 5% Na2CO3, removal of the insol. substance, and recrystn. from alc. gives 0.7 g. 5-benzamidopyrimidazole (III), needles, m. 163-5°. Addition of 4.5 g. MeI to 1.5 g. 2-methylpyrimidazole, heating at 100° for 1 hr., removal of the excess MeI, and recrystg. from MeOH gives 2.8 g. 2-methylpyrimidazole-MeI, needles, m. 190-2°. Heating 1 g. 2-amino-5-iodo-pyridine (IV) with 2 g. BrCH2COMe at 110-20° for 3 hrs., taking up with 25 ml. 10% HCl, treatment with active C, making alkaline with dilute NaOH, taking up with ether, and recrystg. from C6H6 gives 0.2 g. 2-methyl-5-iodopyrimidazole, yellow prisms, m. 151-2°. Boiling 2 g. IV, 3 g. MeCOCHBrCO2Et, and 5 ml. AcOH for 2 hrs., removing the AcOH, making alkaline with NaOH, and recrystg. from MeOH gives 0.1 g. Et 2-methyl-5-iodo-5-pyrimidazole-carboxylate, yellow prisms, m. 134-5°.

IT 860257-92-7P, Imidazo[1,2-a]pyridine, 6-benzamido-
RL: PREP (Preparation)
(preparation of)
RN 860257-92-7 CAPLUS
CN Benzamide, N-imidazo[1,2-a]pyridin-6-yl- (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	208.06	386.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-30.40	-30.40

STN INTERNATIONAL LOGOFF AT 19:26:22 ON 25 NOV 2008